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Almost all aspects of life are engineered at the molecular level, and 
without understanding molecules we can only have a sketchy 
understanding of life itself. 
Francis Crick (1988), What Mad Pursuit: A Personal View of Scientific 
Discovery, p. 61 
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SUMMARY 
 
This Thesis work describes mainly Synchrotron X-rays Diffraction Studies on 
complexes between Transthyretin (TTR) and various ligands. TTR is a naturally-
occurring protein in humans that performs different and relevant biological and 
physiological functions, such as the transport of Vitamin A and Thyroid Hormones, 
particularly T4. Nevertheless, in humans the onset of TTR point mutations can lead, 
in most cases, to deleterious effects for the organism. This is because such mutations 
induce the dissociation of TTR, which in its native state is a tetramer, and this leads 
to amyloid fibrils formation: these protein aggregates are the conditio sine qua non 
for the development of important and serious forms of amyloidosis in different 
organs. Liver transplantation was the first therapeutic solution to amyloidosis caused 
by TTR mutants: however, over the years, it became necessary to find alternatives, 
less invasive and easier to implement and, to date, the most promising treatment is 
the use of small molecules able to kinetically stabilize the TTR tetramer preventing, 
consequently, the dissociation. The understanding, at the molecular and structural 
level, of the interaction between these drugs and the specific binding sites on TTR is 
also an indispensable condition for a more rational design of these dissociation 
inhibitors, in order to obtain molecules more effective, specific and selective. The 
relative ease with which the TTR·ligand complexes co-crystallize, joined to the 
continuous advancement and progress made in the field of X-ray Diffraction with 
Synchrotron sources, allow to obtain three-dimensional models able to sketch out 
with sufficient accuracy the details of the interaction, placing the groundwork for an 
optimized search of most powerful candidates in the treatment of TTR amyloidosis. 
In addition, the structural study of complexes between TTR and various ligands has 
allowed not only the acquisition of more information useful for the rational design of 
new drugs but, at the same time, they have placed new and fascinating questions of 
interest not only to the community of Crystallographers. For example, it remains 
unclear how it is possible that the two binding sites on TTR, despite the fact that they 
are related by a rotation axis of order 2 (both crystallographic and molecular), are not 
equivalent with respect to their binding capacity, being characterized by two 
different affinity constants. As often happens, the answer to a question generates 
many others: after all, isn’t this the major driving force of Scientific Research and, 
more generally, of the Search of Knowledge and Truth?  
A large part of the Thesis work involves computational processing of experimental 
diffraction data obtained through Synchrotron X-rays, their use in structural 
determination, refinement of the model and its interpretation. Among the ligands 
involved in the study there are thyroxine, as well as other small molecules of proven 
therapeutic efficacy, one of which is already on the market as commercial drug for 
the treatment of TTR amyloidosis. Although the structure for most of the complexes 
was already solved, for some of them it was possible to refine the PDB model 
through the analysis of crystals able to diffract to a better resolution, while, for 
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others, it was possible to obtain for the first time the structural model. In all cases, 
relatively to the known structures, it has been verified that the ligands bind as already 
reported in the literature, with a singular exception in which the binding mode has 
proved to be the opposite to what was expected: for this case, two possible 
explanations have been advanced to justify the discrepancy between the two models. 
Finally, this Thesis work is also concerned with the expression and purification of 
another totally different protein, unrelated to TTR, the HtrA protease from 
Campylobacter jejuni (Cj). The goal in this case was its crystallization and structure 
determination through X-ray Diffraction. Cj shares several common features with 
microorganisms of the genus Helicobacter, among which the best known is, without 
any doubt, Helicobacter pylori (Hp): both are responsible for colonization of the 
digestive tract of most humans and for the ability, under certain conditions, to cause 
gastrointestinal diseases such as ulcers, gastritis and gastric cancer. In recent 
decades, many efforts were made to identify the factors responsible for the virulence 
of pathogenic strains of Campylobacter, Helicobacter and many others: however, to 
understand the underlying mechanism of virulence it was necessary to clarify the 
crystal structure of these factors and in this context the X-ray diffraction has been, 
and indeed still holds, the record in terms of accuracy and reliability of the 
information obtained through it. In the case of Hp, one of the demonstrated causes of 
its virulence is the HtrA protease, which plays a similar role in many other 
prokaryotic microorganisms. Attempts to isolate, purify and crystallize such 
protease, however, have proved unsuccessful because of its intrinsic instability: 
given the similarity with the strains of Campylobacter and the common mechanism 
of action of HtrA of different bacteria, it has been suggested to infer the Hp-HtrA 
structure from that of Cj-HtrA. Being able to obtain crystals of the latter makes 
possible to obtain the structure of it through SeMet isomorphous derivatives using 
SAD/MAD (Single- and Multi-wavelength Anomalous Diffraction) techniques or, 
possibly, through Molecular Replacement (MR) owing to the high sequence 
homology with other known HtrA. This was confirmed through Bioinformatics 
analysis, which has also established a high degree of homology with the amino acid 
sequence of the Hp-HtrA: this could be the starting point for the resolution of the Hp-
HtrA structure, together with a 3D Modelling proving a good structural similarity 
between the two proteins. The possibility of solving, through MR, the structure of 
Cj-HtrA is also reinforced by the results of two independent modelling, based on the 
same principle, which lead to identify, in the PDB, the same structure (an HtrA from 
E. coli) as the most similar. The final part of the Thesis focuses on the use of 
Molecular Biology techniques for expression and purification of Cj-HtrA. These 
attempts have proven to be hard: during the different trials, it has been shown that 
Cj-HtrA is susceptible to degradation, through a series of intermediate fragments, 
and this even by adopting all the possible experimental attentions. In light of this, it 
was decided to continue the study on a Cj-HtrA protease having a single specific 
mutation in the active site, in order to reduce its proteolytic activity, increase its 
stability and improve, therefore, its expression.  
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The thesis is divided into two parts: in the first chapter, the main part of the project is 
emphasized. In this regard, an introduction to transthyretin is presented, highlighting 
its biological roles, the information known about its structure and that of its 
complexes, its implication in various amyloidosis and the central role played by X-
ray Diffraction in the search of new therapeutic molecules. Afterwards, the results 
obtained from processing of experimental diffraction data are presented and 
discussed. The second part of the work on Cj-HtrA protease is presented in Part II: 
after an introduction on the main bacterial strains that use it for their virulence, its 
functions in various organisms and structures solved to date, the results obtained 
after various expression and purification trials are shown and critically analyzed. 
The entire Thesis work was carried out in the Laboratory of Structural Biology 
directed by Prof. Giuseppe Zanotti at the Department of Biomedical Sciences of the 
University of Padua. 
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SOMMARIO 
 
Il presente elaborato di Tesi Magistrale concerne principalmente gli studi di 
Diffrazione di Raggi X prodotti da sorgente di Sincrotrone di complessi fra la 
proteina Transtiretina (TTR) e diversi suoi leganti. La Transtiretina è naturalmente 
presente nell’organismo umano (e non solo) dove assolve importanti funzioni 
fisiologiche e biologiche, fra le quali si annoverano il trasporto della Vitamina A e 
degli ormoni tiroidei, particolarmente T4. Tuttavia, diverse sono le cause che, 
nell’uomo, possono determinare l’insorgenza di mutazioni puntiformi della TTR e 
che, abbastanza spesso, si rivelano deleterie per l’organismo. Questo avviene perché 
le mutazioni inducono la dissociazione della TTR, che allo stato nativo è un 
tetramero, a formare fibrille amiloidi le quali rappresentano la conditio sine qua non 
per lo sviluppo di importanti e gravi forme di amiloidosi a carico di diversi organi. Il 
trapianto di fegato ha rappresentato la prima soluzione terapeutica alle amiloidosi 
causate da mutanti della TTR: tuttavia, nel corso degli anni si è reso necessario 
trovare alternative meno invasive e di più facile attuazione e, ad oggi, il trattamento 
più promettente riguarda l’uso di piccole molecole in grado di stabilizzare 
cineticamente il tetramero della TTR, prevenendone di conseguenza la dissociazione. 
La comprensione, a livello molecolare e strutturale, dell’interazione fra questi 
farmaci e i siti di legame specifici sulla TTR rappresenta anch’essa una condizione 
indispensabile per un disegno più mirato e razionale di tali inibitori della 
dissociazione, al fine di ottenere molecole sempre più efficaci, specifiche e selettive. 
La possibilità di co-cristallizzare la TTR insieme a diversi leganti, congiuntamente ai 
continui avanzamenti e progressi ottenuti nel campo della Diffrazione di Raggi X 
con sorgente di Sincrotrone, permette di ottenere modelli tridimensionali capaci di 
delineare con sufficiente accuratezza i dettagli dell’interazione, ponendo così le basi 
per una ricerca ottimizzata di candidati più potenti nel trattamento delle amiloidosi 
da TTR. In aggiunta, lo studio strutturale dei complessi fra la TTR e vari leganti ha 
permesso non solo di acquisire maggiori informazioni utili per il design razionale di 
nuovi farmaci ma ha, nel contempo, posto nuovi ed affascinanti interrogativi 
d’interesse non solo alla comunità dei Cristallografi. Ad esempio, rimane ancora da 
chiarire come sia possibile che i due siti di legame della TTR, nonostante il fatto che 
siano correlati da un asse di rotazione di ordine 2 (sia cristallografico che 
molecolare), non siano però equivalenti rispetto alla loro capacità di legame, in 
quanto caratterizzati da due differenti costanti di affinità. Come sempre accade, 
rispondere a una domanda ne genera molte altre: del resto, non è forse questo il 
motore della Ricerca Scientifica e, più in generale, della Ricerca della Conoscenza e 
della Verità?  
Larga parte del presente lavoro di Tesi riguarda l’elaborazione computazionale di 
dati provenienti dall’analisi di cristalli di complessi TTR·legante attraverso Raggi X 
ottenuti da Sincrotrone, il loro utilizzo nella determinazione strutturale, affinamento 
del modello e sua relativa interpretazione. Fra i leganti coinvolti nello studio, si 
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annovera il legante naturale T4, così come altre piccole molecole di comprovata 
efficacia terapeutica, una delle quali già sul mercato come farmaco commerciale per 
il trattamento delle amiloidosi da TTR. Nonostante di parte dei complessi fosse già 
nota la struttura, per alcuni di essi si è stati in grado di perfezionare il modello 
precedente attraverso l’analisi di cristalli capaci di diffrangere ad una migliore 
risoluzione, mentre per altri è stato ottenuto per la prima volta il modello strutturale. 
In tutti i casi, relativamente alle strutture note, è stato verificato dai dati 
sperimentalmente ottenuti che il legante si lega come già riportato in letteratura, con 
una singolare eccezione nella quale la modalità di binding si è rivelata essere opposta 
a quanto atteso: per questo caso, due soluzioni in grado di spiegare l’incongruenza 
fra i due modelli strutturali sono state avanzate. 
Infine, il presente lavoro di Tesi ha riguardato anche l’espressione e la purificazione 
della proteasi HtrA da Campylobacter jejuni (Cj), con l’intento di riuscire a 
cristallizzarla e poterne determinare la struttura attraverso la diffrazione di raggi X. 
Cj condivide diverse caratteristiche con i microorganismi del genere Helicobacter di 
cui il più noto è, con tutta probabilità, Helicobacter pylori (Hp): con esso condivide, 
ad esempio, la colonizzazione dell’apparato digerente della maggior parte degli 
esseri umani (e non solo) e la capacità, in determinate condizioni, di determinare 
l’insorgenza di patologie gastrointestinali di varia natura fra cui ulcere, gastriti e 
neoplasie gastriche. Negli ultimi decenni, molti sforzi sono stati profusi 
nell’identificare i fattori di virulenza responsabili per la patogenicità dei ceppi di 
Campylobacter, Helicobacter e molti altri: per comprendere, però, il meccanismo 
alla base della loro virulenza è stato necessario chiarire la struttura di tali fattori, e in 
questo contesto la Diffrazione di Raggi X ha avuto, e del resto detiene ancora, il 
primato in termini di accuratezza ed attendibilità delle informazioni ottenibili 
attraverso essa. Nel caso di Hp, una delle cause dimostrate della sua virulenza è da 
imputare alla proteasi HtrA, che gioca un ruolo analogo in molti altri organismi 
procarioti. Tentativi di isolare, purificare e cristallizzare tale proteasi si sono però 
rivelati vani a causa della sua instabilità: data la similitudine con i ceppi di 
Campylobacter ed il comune meccanismo di azione delle HtrA dei diversi batteri, è 
stata avanzata l’ipotesi di inferire la struttura dell’HtrA di Hp da quella della HtrA di 
Cj. Riuscire ad ottenere i cristalli di quest’ultima permetterebbe di ottenerne la 
struttura attraverso i SeMet derivati isomorfi sfruttando le tecniche SAD/MAD o, 
come si ritiene più probabile, attraverso Molecular Replacement (MR) data l’alta 
omologia di sequenza con altre HtrA note. Ciò è stato confermato attraverso 
un’analisi Bioinformatica, la quale ha oltremodo sancito un’elevata omologia della 
sequenza amino acidica anche con la proteasi HtrA di Hp: questo potrebbe essere il 
punto di partenza per la risoluzione (con metodi ab initio o attraverso Molecular 
Dynamics) della struttura della HtrA di Hp, insieme ad un Modelling 3D che 
comprovi una buona somiglianza strutturale fra le due proteine. La possibilità di 
risolvere, attraverso MR, la struttura della HtrA di Cj è rafforzata anche dal risultato 
di due Modelling indipendenti, ma basati sullo stesso principio, che portano ad 
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identificare, nel PDB, la stessa struttura (una HtrA di E. coli) come la più affine dal 
punto di vista strutturale.  
La parte sperimentale della Tesi ha riguardato l’utilizzo degli strumenti della 
Biologia Molecolare per l’espressione e la purificazione dell’HtrA di Cj. Tali 
tentativi si sono tuttavia rivelati ardui: durante le diverse prove, è stato infatti 
dimostrato che la proteasi HtrA da Cj è suscettibile a facile degradazione, attraverso 
una serie di frammenti intermedi, e questo anche adottando le maggiori accortezze 
sperimentali. Alla luce di ciò, è stato deciso di proseguire lo studio su una proteasi 
HtrA da Cj avente una mutazione specifica nel sito attivo, in modo tale da ridurne 
l’attività proteolitica, aumentarne la stabilità e migliorare, quindi, la sua espressione, 
purificazione e cristallizzazione. 
La Tesi è suddivisa in due parti: nel primo capitolo viene dato risalto alla parte 
principale del Progetto. A tal proposito, si presenta un’introduzione alla 
Transtiretina, evidenziando i suoi ruoli biologici, le informazioni note riguardo la sua 
struttura e quella dei suoi complessi, la sua implicazione in diverse amiloidosi ed il 
ruolo centrale rivestito dalla Diffrazione di Raggi X per la ricerca di nuove molecole 
terapeutiche. Quindi, sono presentati e discussi i risultati ottenuti dall’elaborazione 
dei dati sperimentalmente ottenuti. La seconda parte dell’elaborato, invece, concerne 
la proteasi HtrA da Cj: dopo un’introduzione sui principali ceppi batterici che la 
utilizzano ai fini della loro virulenza, sulle sue funzioni in vari organismi e sulle 
strutture ad oggi risolte, vengono mostrati e analizzati criticamente i risultati ottenuti 
a seguito delle diverse prove di espressione e purificazione effettuate. 
L’intero lavoro di Tesi è stato svolto presso il Laboratorio di Biocristallografia del 
Prof. Giuseppe Zanotti, Dipartimento di Scienze Biomediche dell’Università di 
Padova. 
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1 INTRODUCTION 
 
The first Chapter introduces Transthyretin outlining the key aspects regarding its 
biological functions, structure (alone and with different ligands) and the implication 
of different mutants in TTR amyloidosis. Furthermore, the molecular bases of 
amyloidogenesis, along with past and current therapeutic treatments, are discussed. 
In particular, emphasis is given to the treatment with small molecules as drugs and to 
the role of X-ray Diffraction in the understanding of the interaction between TTR 
and such ligands.  
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1.1 General considerations on TTR 
Transthyretin (TTR) is a protein present in the extracellular fluids, mainly serum and 
cerebrospinal fluid (CSF) [1], of different vertebrate species. Crystal structures are 
available for TTR from mammals [2] [3] [4], chicken [5] and fish [6] [7]. Its 
localization in the organism has been confirmed, among the various techniques, also 
by detection of TTR mRNA [8] [9] [10]. TTR derives its first name, prealbumin, 
from the fact that, on electrophoresis gels, it run faster than albumin; however, the 
actual name reflects its biological and physiological role since the acronym stays for 
Transporter of Thyroxine and Retinol molecule. Human transthyretin (hTTR) was 
first crystallized in 1966 by Haupt & Heide and, in the following decade, the 
complete amino acid sequence [11] and the crystal structure were determined. 
Combined, these data provided important structural information about TTR and, in 
subsequent years, more defined crystal structures [12] [13] [14], near to atomic 
resolution [4], revealed new insights crucial in explaining its functions. To date, over 
200 crystal structures are deposited in the Protein Data Bank (PDB) and there is an 
urgent need to summarize and explain this large amount of information with the 
purpose of comprising biological functions and improving actual therapeutic 
treatments for diseases associated with TTR [15]. 
 
1.2 Biological functions  
It is believed that TTRs probably evolved in a prevertebrate species by a duplication 
event involving the gene that encodes the enzyme 5-hydroxyisourate hydrolase (5-
HIU) [16] [17]. This enzyme belongs to the transthyretin-related protein (TRP) 
family, which comprises proteins that share with TTRs essentially the same tertiary 
and quaternary structures and that are present in a wider range of species (bacteria, 
plants and animals). Moreover, TRPs are unable to recognize thyroid hormones. 
They are involved in purine catabolism, particularly in the hydrolysis of 5-HIU [18] 
[19] [20] [21] [22] [23] [24] [25]: so, TTR and 5-hydroxyisourate hydrolase 
(HIUase) are closely related phylogenetically and structurally, although performing 
different functions, and a hypothesis to explain the drastic evolution of the function 
(from enzyme to binding protein) has been advanced [26]. TTR (at least in humans) 
is present already at the embryonic stage and its production continues throughout the 
entire life span; liver and brain (choroid plexus) are engaged in its synthesis and 
reverse TTR in the bloodstream and in the CSF, respectively. Here, TTR acts as an 
important carrier of thyroid hormones (THs), T4 in particular, and vitamin A in 
complex with retinol binding protein (RBP) [27]. THs are extremely lipophilic and 
this is the reason why TTRs are indispensable for an adequate distribution of these 
molecules in the body. Nature has developed three main proteins with this aim that 
are, in order of decreasing affinity towards THs: thyroxine-binding globuline (TBG), 
TTR and albumin. In human blood, 99.98% of T4 and 99.8% of T3 are bound to one 
or more of these carriers; nevertheless, it is worth noting that a percentage smaller 
than 3% of TTR binds and transports T4 in blood plasma (major ligands are albumin 
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and TBG) but almost 50% of the TTR binds to RBP in complex with retinol (holo-
RBP) [28] [29] [30] [31] [32]. To investigate further the roles of TTR in the 
organism, diverse knockout mice studies were carried out, although their results were 
in contrast: some TTR knockout mice display normal life span, whereas others reveal 
depressed levels of retinol, RBP and T4 in the blood, suggesting that the protein is 
important in maintaining normal concentrations of this metabolites. However, 
knockout animals are phenotypically normal and fertile [33]. Furthermore, other 
investigations show implications of TTR in the nervous system physiology [34] [35] 
[36] and as a protective agent capable of binding the β-peptide implicated in the 
Alzheimer’s disease, preventing the onset of neurodegeneration [37] [38] [39]. Some 
studies also report on a possible cryptic protease activity of TTR after the 
identification of different substrates, despite the lack of a real proteasic domain [36] 
[40]. Anyway, the main interest about TTR derives from several point mutations 
(more than hundred have been identified) that, in most cases, are the origin of 
different amyloidosis.  
 
1.3 Pathogenesis of TTR amyloidosis 
In 1978 the first study in which the authors suggested the existence of a link between 
TTR and familial amyloid polyneuropathy (FAP) was published, particularly in the 
presence of TTR mutations [41]. To date, more than hundred of these mutations have 
been reported and only a small portion of them are apparently non-amyloidogenic. A 
regularly updated list of mutations together with their primary citations is available 
on the website http://amyloidosismutations.com/mut-attr.php. Amyloidosis is a rare 
disease characterized by an abnormal deposition and accumulation of a protein as 
amyloid fibrils. The most notorious is, probably, Alzheimer’s disease (AD) and the 
related Aβ peptide [42]. Even though peptides and proteins implicated in amyloidosis 
are disease-specific, the amyloid fibrils share the same morphology, irrespective of 
sequence homology, native structure and functions. More than a decade ago it was 
first proposed the amyloid hypothesis, which states that the accumulation of Aβ in 
brain tissue is the primary driver of AD-related pathogenesis. Amyloid hypothesis is 
currently lacking in detail and certain observations do not fit easily with the simplest 
version of it: at present, there are more recent and broadly supported variations of 
this hypothesis [43] [44] [45]. TTR amyloid fibrils are responsible not only for FAP, 
but also for senile systemic amyloidosis (SSA), familial amyloid cardiomyopathy 
(FAC) and central nervous system selective amyloidosis (CNSA) [46] [47] [48]. 
Principal deposition sites are peripheral nerves and/or the heart. Most of the 
FAC/FAP mutations are conservative, that means no important modifications in the 
overall structure of TTR, but a number of mutations (such as V30M, L55P and 
V122I) modify the kinetic and thermodynamic stability of TTR that is a 
homotetramer in the native form. Such kind of mutations alter the tetrameric form 
and lead to the dissociation that, in turn, is responsible for the onset of the 
amyloidosis [49].  
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Dissociation of the tetramer alone is not sufficient for amyloid fibril formation 
because the native monomers originated in this way are not aggregation-competent: 
its partial denaturation is necessary to form an amyloidogenic intermediate that is 
proposed to be a partially unfolded monomer [50].  
 
 
Figure 1.1: Hypothetical TTR amyloidogenesis pathway based on biophysical studies ([51]). 
 
Actually, two different hypotheses have been advanced. The nucleation-dependent 
amyloid formation hypothesis suggests the formation of oligomeric species that can 
act as seeds to induce protein misfolding, as happens in classical crystal growth (with 
an activation energy barrier associated with the process). For the conformational 
changes hypothesis, there must be the tetramer dissociation in order to induce the 
build up of amyloid fibrils [49] [52] [53]. Probably, there is a thermodynamic 
equilibrium between tetramer and native monomers and the latter needs to undergo 
partial denaturation in order to form amyloid fibrils [54]. Based on biophysical 
studies, the TTR amyloidogenesis pathway provides for rate-limiting tetramer 
dissociation (this is true at physiological conditions) that leads to native monomers 
that can either reassociate or partially unfold. The misfolded monomers can 
aggregate via a downhill polymerization to yield a variety of aggregate 
morphologies, including amorphous aggregates and amyloid fibrils. Dissociation and 
aggregation are extremely slow under physiological conditions but a pH reduction, 
for example in lysosomes [52] [53] [55] [56] [57] [58] [59] or in the presence of 
metal ions such as Zn
2+
 [60] [61] dramatically increase the rate of the process, 
favouring amyloidogenesis. These studies show that the rate of fibrils formation is 
pH dependent and that some TTR mutants - as L55P - can dissociate into 
amyloidogenic monomers at neutral pH and 37°C, unlike wt-TTR, as a consequence 
of the reduced activation barrier. L55P is then more sensible toward acidic conditions 
and it starts to dissociate at pH values at which wt-TTR is still in the tetrameric form. 
Crystal structure studies can provide deep insights into amyloidogenesis, but the 
clear influence of pH states the necessity to collect data from crystals grown at pH 
values low enough: unfortunately, at present, many structures were solved using 
crystals grown in non amyloidogenic conditions and acidic crystallization conditions 
will likely become a requirement for future studies [63].  
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However, among the structures solved to date and obtained from crystals grown in 
acidic conditions there are few of them that do not show significant conformational 
changes. This is probably due to the tendency of TTR to select, during crystal growth 
stages, only symmetric conformations. Taking into account the possibility of having, 
in solution, an equilibrium between native TTR and the same protein in which some 
conformational changes occurred, it can be speculated that the system selects only 
TTR molecules non altered by the lowering in pH. This, in turn, is probably caused 
by the specific crystal packing (i.e., by the specific orthorhombic point group in 
which most of the TTR crystals grow easily). No one has made a systematic 
screening of TTR crystal forms in acidic conditions but it is likely that this will shed 
light on this still open question. 
 
1.4 Structure of wt-TTR 
When Colin Blake solved, for the first time in 1971, the structure of TTR at a 
resolution of about 6Å [62] he noticed that, among the different proteins known at 
the time of the discovery, TTR was unique owing to the high content in β-sheets 
characterizing its secondary structure. TTR is a homotetramer of 55kDa in which 
each of the four subunits (named A, B, C and D) is composed of 127 amino acids.  
 
 
Figure 1.2: a) Ribbon representation of subunit A of TTR tetramer, showing secondary structural 
elements; b) Ribbon representation of TTR tetramer with the T4 hormone binding sites and the C2 axis 
that relates dimers AB (the content of the asymmetric unit) and CD; c) View of the TTR tetramer 
rotated 90° to show the central channel and d) View of one T4 binding site with T4 shown in both the 
symmetry-related conformations ([49], [60]). 
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To date, 14 wt-TTR structures are deposited in the PDB: they usually crystallized in 
the same orthorhombic space group P21212 and they have approximate lattice 
dimensions: a = 43Å, b = 85Å and c = 64Å. The asymmetric unit of the crystal 
contains the AB dimer (subunits A and B), while the CD dimer is generate through 
the crystallographic two-fold axis, corresponding to one of the C2 symmetry axis 
present in the protein. Often, monomers C and D are also named A’ and B’, 
respectively (this denomination will be used later in the text). Each subunit contains 
2 antiparallel β-sheets formed by the strands A-D and E-H arranged in a β-barrel 
topology, with a short α-helix (EF helix) localized between strands E and F. In TTR, 
there are 2 different dimer/dimer interfaces: the more strong AC/BD interface, 
stabilized by interstrand hydrogen bonds, and the weaker AB/CD interface, which 
consists of hydrophobic interactions. The latter are responsible for the presence of 
two funnel-shaped hydrophobic T4 binding sites that passes through the C2 axis. In 
each binding site there are two types of cavities, the narrow Inner cavity and the 
larger Outer cavity with three pairs of depressions named Halogen Binding Pockets 
(HBPs) in which the iodine atoms of the natural ligand thyroxine are localized. 
Despite two different affinity constants were determined for the binding of this 
ligand to the binding sites on TTR, whose order of magnitudes are 10
6
 and 10
8
 M
-1
 at 
physiological pH [29] [64] [65] [66], crystal structures reveal the presence of T4 in 
all of them. Two diverse association constants imply that the two binding sites are 
not equal, despite their formal equivalence due to the presence of a 2-fold rotation 
axis. This also means that T4 binds with a negative cooperativity mechanism, as 
demonstrated in solution [65] [66]. It is likely that the binding event of the first T4 
molecule causes conformational changes in TTR, rendering the second site less 
suitable for binding. Inspections of the electron density, molecular dynamics 
simulations and other evidences seems to confirm this hypothesis and, probably, this 
arises from a certain degree of flexibility of some portions of TTR [67] [68] [69]. 
Recent neutron diffraction studies on perdeuterated TTR, able to visualize and locate 
with more accuracy hydrogen (D-substituted) atoms with respect to X-ray 
diffraction, yield new structural information [70]. The authors found a single water 
molecule in the channel (interacting with Ser117A and Ser117A’), present only at the 
A/A’ interface (site A): as a result, the entry to the binding pocket is wider for the B 
than for the A pocket and this would be responsible for the different measured 
affinities.  
 
1.5 Molecular basis of amyloidogenesis 
In a paper published in 2000, some authors investigated 23 different structures, 
comprehensive of wt-TTRs, amyloidogenic and non amyloidogenic mutants and 
different TTR·ligand complexes [4]. They concluded that the differences considered 
of importance in the amyloidogenesis were insignificant; others studies [14] [71] also 
concluded that lowering the pH does not induce any significant conformational 
changes in wt-TTR crystal structures.  
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Only in 2008 the first evidence of a conformational changes in the structure of wt-
TTR at pH 4.0 and 3.5 was presented [72]. In particular, at pH 4.0 in the subunit B, 
the EF-helix-loop composed of the EF-helix, the EF-loop and part of β-strands E and 
F, display significant conformational flexibility that increases at pH 3.5, acting as 
possible initiation mechanism for TTR amyloidogenesis. Lowering the pH induces 
the protonation of some residues of the EF-helix-loop region suggesting a possible 
origin for the conformational changes. Some metal ions, such as Zn
2+
, causes similar 
changes in a manner comparable to that shown by protons; already at physiological 
conditions and if present in sufficiently high concentrations, zinc ions induced 
amyloid fibrils formation perturbing the EF-helix-loop region [60] [61]. However, 
the effect its greatest at acidic pH: this was also seen in a study on the complex TTR 
F87M/L110M:Zn
2+
. It was clearly demonstrated that Zn
2+
 binding near the EF-helix-
loop region perturbs it, inducing a significant conformational change that raises the 
flexibility, particularly at low pH values [60]. The crystal structure determination of 
another mutant, TTR G53S/E54D/L55S, reveals another type of conformational 
change, called β-slip, because of a dramatic shift in the positioning of β-strand D 
[73]. This β-shift involved three residues because it places Leu58 at the position 
normally occupied by Leu55 that is mutated to serine: the effect has consequences on 
protein-protein interactions and on the crystal packing, leading to a new model for 
amyloidogenesis. Presently, the comprehension of amyloidogenesis is based on the 
movements of EF-helix-loop region upon acidification and/or the presence of metal 
ions and on the β-slip induced by some mutations. Finally, there are two possible 
explanations for the apparent absence of significant conformational changes in 
different crystal structures: i) in low pH crystallization drops a heterogeneous 
ensemble of TTR molecules in equilibrium is present such as partially denatured 
tetramers and native tetramers, but the crystal selects only the conformation of the 
predominant species; or, ii) TTR has a natural propensity in packing itself as a 
symmetric tetramer, hindering the determination of misfolded and/or unfolded 
monomers. 
 
 
 
Figure 1.3: a) Monomer A in native TTR (the position of the triple mutation is shown in green) and 
b) Monomer B from TTR G53S/E54D/L55S ([73]). 
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1.6 Molecular basis for the treatment of TTR amyloidosis 
Until a few years ago, the general treatment for TTR amyloidosis was liver 
transplantation, which enables the substitution of the mutant TTR with the wild type 
TTR. However, this strategy has to deal with some drawbacks (shortage of donors, 
the need to resort to surgery for both donor and recipient and high costs) and 
different strategies are being studied. The onset of amyloidosis has as first stage 
tetramer dissociation and, as a consequence, whatever molecule able to inhibit this 
step is a potential candidate in TTR amyloidosis treatment. So, a promising therapy 
consists in using small molecules capable of binding to TTR and, through kinetic 
stabilization, to block the protein in its tetrameric form, preventing deleterious 
dissociation. Besides these treatments, other possibilities are currently under study 
such as gene therapy, plasma exchange, immune therapy [74] and others [75]. 
Regarding the former, different solutions are possible and they span from ribozymes, 
catalytic RNA molecules used to inhibit gene expression cleaving specifically the 
mRNA derived from the transcription of the defective gene [76] [77], to antisense 
oligonucleotides, which act on the same target (mRNA) taking advantage of the 
complementarity between the two nucleic acid sequences [78]. Single stranded 
oligonucleotides [79] and RNA interference [80] are also under study. The gene 
therapy also emerges as a possible treatment in heterozygote patients which present 
an amyloidogenic mutation like V30M on one allele and a stabilizing mutation on the 
other (for example, T119M) [55]. The association of these two mutations seems to 
protect his carriers from the severe form of the disease: trans-suppression refers to 
the concept that a T119M TTR subunit has the ability to significantly stabilize the 
V30M-comprised TTR tetramer against dissociation and misfolding [81]. The 
T119M suppressor subunit could be incorporated post-secretion into the quaternary 
structure of TTR using a subunit-exchange strategy, or during biosynthesis using the 
aforementioned gene therapy approach before secretion [82]. Lastly, immune therapy 
consists in the immunization through an amyloidogenic mutant TTR: this entails the 
production of a specific antibody that reacts with amyloid deposits determining a 
reduction/inhibition of TTR deposition, as demonstrated for Y78F TTR [83]. 
Nonetheless, the use of small drugs is the most conservative therapeutic strategy 
because it prevents the process of amyloidogenesis from the beginning. 
 
1.7 Using small drugs in the treatment of TTR amyloidosis 
Using small drugs are currently under investigation in the treatment not only of TTR 
amyloidosis but also for other amyloidosis as ALS (Amyotrophic Lateral Sclerosis), 
in which SOD aggregation plays an important role [84], or in lysozyme amyloidosis 
where variants of lysozyme render the protein amyloidogenic [85] [86]. However, 
pharmacologic treatment of TTR amyloidosis must take into account the structure of 
TTR, in other words the dimensions and binding affinities of the two binding sites 
for thyroxine. Most of the molecules with a demonstrated activity against tetramer 
dissociation, briefly called “inhibitor”, bind to TTR with a negative cooperativity 
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mechanism. Such molecules are typically composed of two aromatic rings, linked 
directly or by means of linkers with different chemical nature [51]. Generally, one 
aromatic ring is substituted with polar groups, while the other ring displays halogen 
atoms, alkyl groups or a combination of both. Polar substituents (i.e., carboxylates or 
phenolates) are complementary to positive charges on side chains of Lys15 or Glu54 
in the outer binding site, whereas the other groups are compatible with the 
hydrophobicity of the inner binding cavity, occupying some HBPs. There exist two 
different binding modes exhibited by ligands: in the so called forward binding mode, 
the aromatic ring bearing the anionic substituent is oriented towards the outer 
binding pocket, thanks to favourable electrostatic interactions. On the contrary, in the 
reverse binding mode the carboxylate bearing the aryl ring prefers the inner binding 
pocket (but this usually does not happen). As proved in vitro, the natural ligand T4 
binds to TTR preventing amyloid fibrils formation and does so by stabilizing the 
tetramer against dissociation: the binding of small molecules to TTR raises the 
activation energy barrier necessary for tetramer dissociation, preventing amyloidosis 
[87]. Is also emphasizes the fact that more than 99% of T4 sites on human TTR are 
unoccupied and, as a consequence, they are eligible targets for small drugs; these 
molecules bind in a forward or in a reverse binding mode depending on polarity and 
dimensions of the substituents to the aromatic rings. Among such bi-aryl systems, 
some non steroidal anti-inflammatory drugs (NSAIDs) like the approved flufenamic 
acid (Flu), Diflunisal (Diflu) and Diclofenac show good complementarity with the 
hormone binding sites on TTR; they are effective inhibitors owing to their structure 
and not because their NSAIDs activity. Even natural compounds with bi-aryl 
scaffold, such as resveratrol, were crystallized in complex with TTR and tested, 
unveiling very promising percentages of inhibition over fibrils formation in acidic 
conditions [88]. Due to their efficacy, several structures of TTR:NSAIDs inhibitor 
complexes were solved [89] [90] and some information were used to develop new 
drugs like iodo-Diflu and analogues, that showed an improved inhibitory effect 
thanks to additional iodine atoms mimicking those found in thyroxine [91]. These 
structures suggest, also, other effective molecules based on a tryciclic ring system 
[81] [83], in particular Tafamidis, a benzoxazole derivative approved and marketed 
for the amelioration of FAP [74] [92]. However, some compounds show a few 
drawbacks: for example, the main defect of NSAIDs is that they inhibit not only the 
mutant TTR, but also COX enzymes, resulting in a series of different collateral 
effects [67]; in addition, TTR circulates in high concentrations in the serum and the 
drug might be delivered in high doses to be effective. Last but not least, inhibitors 
circulating in the bloodstream should bind selectively only TTR and not all the other 
proteins present (~4000 additional proteins in plasma). These are the reasons for 
which drug design must keep in consideration the potency of a compound as 
inhibitor but, also, side and off-target effects. Some of the co-crystal structures 
previously mentioned suggest that it is possible to design a single molecule that 
occupies, simultaneously, both binding sites on TTR: these molecules were named 
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bivalent inhibitors and they might overcome problems such as negative cooperativity 
and affinity towards COX-1 and COX-2. 
 
1.8 Structures of TTR complexed with main ligands 
1.8.1 Structure of TTR with T4 
Blake et al. solved the crystal structure of TTR in 
complex with T4 and then investigated its mechanism 
of binding: they found that T4 binds in the two 
symmetry equivalent sites, deeply buried along the 
central channel; since the electron density was not 
very clear, both for the relatively low resolution and 
for symmetry reasons (see below), they tryed to 
locate the iodine substituents of the ligand [12]. In 
the ensuing years, other structures were solved, 
confirming that the crystals are orthorhombic, 
belonging to the same space group of TTR, P21212, 
with two monomers in the asymmetric unit [93]. In 
consequence of the intrinsic 2-fold symmetry, T4 
binds in two symmetry-related conformations with 
50% occupancy, but to distinguish the two is a 
challenge also at high resolution. T4 fully lock into 
the central channel making favourable bonding 
interactions and stabilizing TTR in its native 
tetrameric form. As already described, each T4 site is 
composed of two different (inner and outer) pockets 
and is equipped with three pairs of HBPs: the 
number and the nature of the aminoacids exposed by 
these cavities determine the affinity and the binding 
mode of T4 and T4 analogues. The hormone Iodine 
atoms protrude towards the halogen binding pockets: in particular, in the inner cavity 
the 3’ and 5’ iodine atoms are linked to the HBP2/2’ and HBP3/3’ pockets and the 4’ 
hydroxyl group establish water-mediated hydrogen bond interactions with the same 
groups of Ser117/117’ and Thr119/119’. Depending on whether the carboxylate 
bearing aryl ring of T4 orients towards the outer or the inner binding pocket, the 
ligand displays the forward or the reverse binding mode, respectively. It is interesting 
to note the remarkable capability of TTR to accommodate various ligands in 
different conformations: this open the possibility to design small drugs as inhibitors 
of amyloid fibrils formation but, on the other hand, the great capacity to bind several 
molecules make a challenge finding a selective and specific inhibitor. 
 
Figure 1.4: Interaction of T4 
with  one of the T4 binding 
site on TTR. The ligand is 
shown in both of its 
symmetry-related 
conformations (green and 
blue), in the forward binding 
mode ([63]). 
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1.8.2 Structures of the TTR·holo-RBP complexes 
Trans-retinol, one of the various forms of animal vitamin A, is a small diterpenoid 
molecule implicated in diverse functions, like cell differentiation, growth and 
development of embryos, vision and others: inside the organism, it is transported as a 
complex with retinol binding 
proteins (RBPs), a family of 
proteins that act as carriers of the 
different forms of vitamin A in the 
blood. They are small proteins 
(about 21kDa) belonging to the 
lipocalin superfamily, composed of 
a single polypeptide chain 
organized in eight  antiparallel β-
sheets forming a β-barrel with an 
internal cavity well suited for 
retinol. The stability of the 
TTR:RBP complex is significantly 
affected by the presence of retinol 
as a ligand of RBP. On RBP, the 
residues on the loops at the entrance of the β-barrel are the main responsible for 
complex formation: binding of retinol is crucial for the stabilization of RBP loops 
and in turn for the TTR:RBP complex formation. As demonstrated, TTR is unable to 
bind to apo-RBP (without retinol) [94] [95]. Different structures of TTR·holo-RBP 
complexes are deposited, comprising some TTR mutants [30] [31] [96], and are well 
reviewed [97]; despite the presence of four equivalent binding sites on TTR, only 
two of them can bind to RBP as a consequence of steric hindrance. Two different 
quaternary structures were observed for the complex, namely the same and the 
opposite dimer model: in the former, the two RBP molecules interacts with the same 
TTR dimer (AB or CD), whereas in the latter they interacts with subunits on different 
dimers (AC or BD). Holo-RBP interacts with specific regions on three different TTR 
subunits (A, B and D) and because of the presence, at the interface, of the EF-helix-
loop region (highly flexible in acidic conditions or in the presence of Zn
2+
), many 
studies attempt to investigate the role of some residues in this region in the TTR:RBP 
complex formation. 
 
 
 
 
 
Figure 1.5: Representation of the two possible binding 
modes of holo-RBPs to TTR (same dimer model 
indicated by solid arrow and opposite dimer model 
indicated by dotted arrow) ([63]). 
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1.8.3 Structure of the complex TTR·resv 
The structure of TTR:resv complex was 
determined, in view of the promising inhibitory 
activity of the phenolic compound resveratrol 
(resv) [88]. The structure shows that resv fits well 
into the two T4 binding sites; because of the 
intrinsic 2-fold symmetry, resv, as all the other 
ligands, binds in two possible orientations related 
by a rotation of 180° along the channel. 
Interactions between TTR and resv are mediated 
by the stilbene moiety through non polar contacts. 
Two main factors contribute to the potency of 
resv, that is specific hydrogen bonds and 
favourable entropic contributions. The p- hydroxyl 
group is bound deeply in the cavity and is 
involved in hydrogen bond interactions with the 
hydroxyl group of Ser117 and Ser117’. 
Furthermore, the other two hydroxyl groups, 
present at the entry of the cavity, forms hydrogen 
bonds with some ordered water molecules. Favourable entropic contributions derive 
from the release of such ordered water molecules (at higher energy inside the cavity) 
and from the minimal conformational penalty that the system has to pay upon 
binding of the rigid stilbene moiety.  
 
1.8.4 Structure of TTR·Tafamidis complex 
 
 
 
 
 
 
 
 
The recently solved TTR:Tafamidis complex structure at 1.3Å resolution reveals the 
molecular and structural basis of TTR tetramer stabilization by Tafamidis, suggesting 
that the binding stabilizes the weaker dimer/dimer interface against dissociation [98]. 
The 3,5-dichloro substituents occupy HBP3/3’ in the inner binding cavity.  
Figure 1.6: One of the two hormone 
binding of TTR with resv bound in two  
symmetry-related binding modes  
(shown in yellow and green) ([88]). 
Figure 1.7: Ribbon representation of the TTR tetramer with the Tafamidis 
bound. Magnified image of Tafamidis in one of the T4 binding sites ([98]). 
 25 
 
The benzoxazole moiety is inserted in the hydrophobic environment of HBP1/1’ and 
HBP2/2’. In this configuration, the carboxylate substituent is involved in water 
mediated hydrogen bonds with Lys15/15’ and Glu54/54’ of TTR. This combination 
of hydrophobic and electrostatic interactions appears to link adjacent dimers to 
kinetically stabilize the TTR native tetramer. 
 
1.8.5 Structure of TTR·CHF5074 complex 
Crystal structures of wt-TTR·CHF5074 (at pH 7.0) and of I84S TTR·CHF5074 (at 
pH 4.6) complexes were solved and published in the PDB in 2013, at a resolution of 
1.67Å and 1.69Å, respectively [99]. CHF5074 is a fibrillogenesis inhibitor [100] 
[101] [102] and represents a chlorinated derivative of Flurbiprofen [103]; moreover, 
it possesses high binding affinity for 
wt-TTR. It binds to TTR in the 
forward binding mode and its 
position in the complex is relatively 
well defined for both T4 binding 
sites. In particular, the di-chloro 
phenyl ring is deeply buried inside 
the central channel and the 
carboxylic moiety protrudes towards 
the solvent. However, despite a 
well-defined electron density for the 
inner and medium rings, the 
cyclopropane ring and the 
carboxylate end appear poorly 
defined. The ligand makes 
hydrophobic and electrostatic 
interactions with residues lining the 
TTR binding cavities. The former 
are mediated by Leu17/17’, 
Ala108/108’, Leu110/110’ and 
Thr119/119’, whereas the latter are 
represented by four polar contacts. 
From the superimposition with the 
other available structures it can be inferred that CHF5074 stabilizes the native 
structure of the TTR I84S tetramer, as it is able to readjust the altered structure of 
uncomplexed I84S TTR at acidic pH, converting it to that typical of wt-TTR at 
neutral pH. As in the complex of TTR with Diflunisal, it appears that the structure of 
TTR in complex with fibrillogenesis inhibitors remains nearly unchanged at both 
neutral and acidic pH: in other words, the ligand stabilizes the native protein 
structure mostly filling the central channel, while the protein conformation remains 
essentially the same.  
Figure 1.8: Ribbon representation of wt-TTR·CHF5074 
complex and close-up view of one binding site [99]. 
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The final effect is the rigidification of the tetramer and, as a consequence, the 
likelihood of a transition into the altered amyloidogenic conformation (favoured by 
lowering in pH and particularly for the variant I84S) is reduced. 
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1.9 Purpose of the Thesis Project 
 
As discussed in the previous paragraphs, despite the significant difference between 
the two binding constants measured in solution for most of the TTR ligands, the two 
binding sites are very similar in the crystal structures of these complexes, and both 
appear occupied. Only very recently important and robust observations coming from 
X-ray and neutron diffraction and Molecular Dynamics Simulations shed light (in 
part) on the small, though significant, differences between sites A and B that are 
responsible for different geometries for the two hormone binding sites.  
In the present Thesis work the problem is considered from a “crystallographic” point 
of view through the use of the tools offered by X-ray Crystallography. In particular 
the ability of this technique to provide details about the occupation of the sites by 
selected ligands is exploited. Although the ligands used in the present study have 
already been crystallized in complex with TTR and their structures solved, other 
aspects remain to be elucidated. For example, the structures so far determined were 
obtained by soaking the TTR protein crystals with an excess of ligand. The 
preparation of the complexes in solution and the use of a controlled stoichiometry 
ratio can reveal new insights into the mechanism of asymmetric ligand binding; the 
same can be said for mixed complexes, i.e. for complexes between TTR and (at least) 
two different ligands. With the aim of clarifying the ligand preference of TTR, 
attention has been focused either on different complexes with 1:1 stoichiometry ratio 
between protein Transthyretin and small-molecule ligands and on a single mixed 
complex. The question is of interest not only from a theoretical point of view, but it 
could have important therapeutic implications in the use of mixed ligands for the 
treatment of TTR amyloidosis.  
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2. MATERIALS & METHODS 
 
In this Chapter are described the procedures with which co-crystals of the complexes 
were obtained, together with the protocol used to determine the crystal structure of 
TTR·ligand complexes.  
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2.1 Crystal structure refinement of TTR complexes 
2.1.1 Crystallization 
Crystals of TTR·ligand complexes suitable for X-ray diffraction studies were 
obtained in the Group of Prof. Rodolfo Berni at the University of Parma. 
Recombinant human wild type TTR was prepared as described previously in 
literature [71]. Crystals of TTR·ligand complexes were obtained at room temperature 
in about one week by co-crystallization, using the hanging-drop vapour diffusion 
method. Regarding all the 1:1 complexes, the protein (5 mg/ml), in 20 mM sodium 
phosphate at pH 7, was incubated for a few hours with an equimolar quantity of 
ligands solubilized in DMSO. For TTR·ligand excess, the same conditions have been 
used, but the protein was incubated for a few hours with a fourfold molar excess of 
ligands solubilized in DMSO. Drops were formed by mixing equal volumes of the 
solution containing TTR·ligand complexes and of the reservoir/precipitant solution 
(2.0 M ammonium sulfate, 0.1 M KCl, 0.05 M sodium phosphate, pH 7.0).  
 
2.1.2 Data collection and structural determination 
The crystals were directly flash cooled at 77K after fishing from the crystallization 
drops. The datasets concerning the different TTR·ligand complexes were collected at 
the PXIII Beamline of Swiss Light Source synchrotron radiation facility (Villigen, 
Switzerland). 
Datasets were processed with the software XDS [104] and scaled with Scala [105] 
contained within the CCP4 suite [106]. The structures of the TTR·ligand complexes 
were refined starting from the atomic coordinates of the hTTR dimer as a template 
(PDB ID code: 1F41 ([4])). Atomic coordinates of the ligand molecules and 
restraints were obtained through the PRODRG server [107] [108] or the function 
eLBOW implemented in Penix.refine. The models were refined using the package 
Phenix (PHENIX version 1.9-1692) [109] with a maximum likelihood target 
function. After each series of refinements, map visualization and manual adjustment 
of the models were performed using the Coot graphic interface [110]. Water 
molecules were added automatically to the model and were revised and eventually 
adjusted manually using Coot. In the last cycles, TLS refinement was applied.  
Inspection of the electron density in the channel for TTR·ligand complexes  
indicated the presence of the ligands bound in one or both of the TTR binding sites. 
Crystals of hTTR in complex with the various ligands diffracted to a maximum 
resolution between 1.38Å and 1.73Å: this allowed to define, in most cases, details of 
the T4 binding sites and to refine quite carefully the occupancies of the ligands in the 
TTR molecule. All the structures are isomorphous to wild type hTTR: in all cases, 
the crystal lattice is orthorhombic, space group P21212 (Appendix A) and the cell 
parameters are quite similar for all crystals.  
Data collection and refinement statistics are summarized in Table 2.1. 
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Table 2.1: Data collection and refinement statistics. Data were measured at PXIII beamline of Synchrotron Light Source, Villigen, Switzerland. 
Data set TTR·resv 1:1 TTR·resv excess TTR·resv·T4 TTR·T4 1:1 TTR·Tafamidis 
1:1 
TTR·CHF5074 1:1 
Wavelenght  1.00 1.00 1.00 1.00 1.00 1.00 
Cell dimensions            
a, b, c (Å) 42.44, 85.61, 
63.64 
42.94, 85.35, 
63.91 
42.54, 85.63, 
63.83 
42.56, 85.75, 
63.93 
42.42, 85.37, 
63.60 
42.43, 85.07, 
64.11 
Resolution (Å) 42.80-1.39 
(1.46-1.39)* 
42.94-1.38 
(1.46-1.38) 
42.82-1.54 
(1.63-1.54) 
42.88-1.38 
(1.46-1.38) 
42.69-1.73 
(1.82-1.73) 
42.53-1.38 
(1.46-1.38) 
Rmerg 0.032 (0.744) 0.058 (1.275) 0.041 (0.298) 0.052 (0.884) 0.057 (0.324) 0.045 (0.521) 
Rpim 0.015 (0.349) 0.031 (0.605) 0.019 (0.143) 0.026 (0.443) 0.029 (0.171) 0.023 (0.248) 
<I/σ(I)> 24.7 (2.3) 14.6 (1.1) 21.3 (4.9) 14.8 (1.6) 17.4 (3.1) 19.3 (3.2) 
Completeness 
(%) 
99.5 (97.3) 97.4 (92.9) 99.5 (97.3) 99.1 (95.6) 97.7 (88.9) 99.3 (97.9) 
Redundancy 6.4 (6.1) 6.0 (5.9) 6.2 (6.1) 6.0 (5.7) 5.9 (5.1) 6.0 (5.8) 
Refinement 
No. reflections 89471 80196 65091 89075 43322 87717 
Rwork / Rfree 0.168/0.191 0.237/0.266 0.166/0.193 0.170/0.213 0.204/0.262 0.182/0.233 
No. atoms 1975 2107 1966 2013 3740 2068 
Protein 1804 1810 1793 1841 1833 1835 
Solvent/Ligands 171/17 297/17 173/41 172/48 159/40 233/42 
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R.m.s. deviations 
Bond lenghts 
(Å) 
0.009 0.011 0.010 0.012 0.012 0.011 
Bond angles (°) 1.334 1.362 1.287 1.478 1.392 1.345 
Ramachandran plot (%)** 
Favored 98.25 97.83 98.26 97.83 96.52 97.34 
Allowed 1.31 1.74 1.30 1.74 3.48 2.17 
Outliers 0.44 0.43 0.43 0.43 0 0.43 
Rotamer 
outliers (%) 
1.54 0.51 0.52 1.53 1.53 1.53 
Cβ deviations 1 0 0 2 0 1 
 
* Numbers in parentheses refer to the last resolution shell. 
** MolProbity statistics. 
Rsym defined as:       
              
        
 where I is the intensity of a reflection and <I> is the mean intensity of all symmetry related 
reflections j. 
Rp.i.m. defined as:         
   
 
   
            
   
   
        
 where I is the intensity of a reflection, <I> is the mean intensity of all symmetry 
related reflections j and N is the multiplicity.
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3. RESULTS & DISCUSSION   
 
In this Chapter, results obtained from the refinement process of the six complexes 
studied will be illustrated. The results will be presented discussing the overall quality 
of the model obtained after the refinement process, possibly comparing them with 
those previously reported in the literature and, in some cases, analyzing the 
interactions between the ligand and the specific amino acids in the cavities. The 
molecules involved in the complex with the transthyretin are its natural ligand 
thyroxine (T4), the phenolic compound resveratrol, the drug already approved and 
marketed Tafamidis and the promising candidate (involved in the late-phase of 
clinical trials) CHF5074: 
 
                    
                      Figure 3.1: Thyroxine.                                             Figure 3.2: Resveratrol. 
 
                                               
      Figure 3.3: Tafamidis (Vyndaqel).                            Figure 3.4: CHF5074 (CSP-1103). 
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3.1 Crystal structure refinement of TTR complexes 
3.1.1 Structure of TTR·CHF5074 1:1 complex 
As reported for the wt-TTR·CHF5074 complex at 1.67Å, whose crystals were 
obtained with a fourfold molar excess of CHF5074 [99], also with an equimolar 
mixture two molecules of ligand are present in both the sites on the protein, despite 
with different occupancy (Fig. 3.7). The good resolution of the structure (1.38Å) is 
reflected in the quality of the electron density map, into which the model of the 
three-dimensional protein structure is built (a higher resolution of the data means 
higher resolution of the electron density maps, which in turn means higher accuracy 
of the positions of the atoms in the structure). In Fig. 3.5 is reported a selected trait 
from Chain A of the TTR·CHF5074 complex, testifying the quality of the electron 
density map.  
 
 
Figure 3.5: View of the electron density map in chicken-wire representation only for residues from 83 
to 90, chain A, corresponding to a β-sheet trait, from TTR·CHF5074 complex. The map has been 
calculated with coefficients 2           and contoured at 2.0σ level. This electron density map, along 
with all the others in the text, have been produces using the phenix.maps tool with final model and 
reflection files as input and after graphical visualization and adjustments in MacPyMOL. 
 
In particular, the electron density of the ligand is clearly visible from the first stages 
of refinement and this facilitates its placement in the cavity. However, it is worth 
noting that the presence of a crystallographic and molecular twofold axis through the 
cavity in which the ligand is hosted implies the presence of two possible orientations 
of the molecule: this is responsible for an intrinsic disorder in the observed electron 
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density. From Fig. 3.6, it is possible to note that the electron density map is 
sufficiently defined to show both conformations of the ligand inside the cavities. 
 
  
Figure 3.6: View of the electron density map in chicken-wire representation, calculated with 
coefficients 2           and contoured at 2.0σ level only around the ligand (on the left in site B, on 
the right in site A), for CHF5074 bound to wt-TTR. Only one of the two symmetry-related 
conformations is shown in magenta.  
 
From the same Figure, the electron density associated with the two phenyl rings 
appears well defined, whilst the ligand portion comprising the cyclopropane ring and 
the carboxylic group is, in fact, not visible, owing to the flexible nature and the 
reduced interaction of this ligand moiety with some residues. Indeed, when some 
parts of the structure are not so well ordered (due to flexibility), this results in high 
temperature factors (or B-factors) and poor electron density maps. Looking at the B-
factors for the inhibitor molecules in both binding sites (hereinafter referred to as site 
A and site B, because the former is lined by monomers A and A’ and the latter by 
monomers B and B’), it is possible to make two observations. First, in agreement 
with what was said before, the atoms that are part of the cyclopropane ring and of the 
carboxylate end group show higher B-factor values compared to all the other atoms 
of the ligand. Second, apart from one exception, all the atoms of the ligand inside site 
A display a B-factor higher than that of the atoms of the ligand in site B and this is so 
because of the exponential relation that links together occupancy and the temperature 
factor (refining the structure fixing the B values and allowing the occupancy to adjust 
itself show, in fact, that ligand atoms in site A have an average occupancy lower than 
the atoms in site B). Another feature in common with previous results obtained for 
the complex concerns the binding mode of the ligand inside the cavities of the TTR 
tetramer: the inhibitor is bound in the so called forward binding mode, with the di-
chloro phenyl ring embedded inside the cavity and the flexible portion protruding 
outward. 
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Figure 3.7: Stereo view of the TTR·CHF5074 complex in cartoon representation with the secondary 
structure elements, showing the four monomers with different colours (yellow, green, magenta and 
cyan) and the ligands in the hormone binding sites as stick model (for clarity, only one of the two 
conformations is shown for each ligand). Water molecules are omitted. This figure, along with all the 
others (excluded electron density images), have been produces using software MacPyMOL (DeLano, 
2007, MacPyMOL: A PyMOL-based Molecular Graphics Application for Mac OS X. DeLano 
Scientific LLC, Palo Alto, CA.) 
 
Figure 3.8: On the left, view of the TTR·CHF5074 complex along the central hormone binding 
channel with the two ligands shown. On the right, ribbon representation of the same complex coloured 
on the base of the secondary structure elements (helix in red, sheet in yellow and loop in green) with 
the CHF5074 molecules in the T4 hormone binding sites formed between two dimers.  
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Figure 3.9: At the top: hormone binding site structure of the TTR·CHF5074 1:1 complex, showing the 
relevant residues involved in the interaction with the ligand. The representation confirms the model 
previously solved [99]. At the bottom: three magnifications showing the main electrostatic interactions 
inside the cavity, with the measured distances (Å) . 
 
As shown in Fig. 3.9, to visualize the main residues involved in the interaction with 
the ligand inside the cavity a detailed view was created and compared to what was 
already reported in literature [99]. In Fig. 3.9 have been evidenced amino acids 
Lys15 and Leu17 (HBP 1 and 1’), Ser117, Leu110, and Ala108 (HBP3 and 3’) and 
residues Leu17, Ala108, Ala109 and Leu110 (HBP2 and 2’).  
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As introduced in Paragraph 1.8.5, both TTR-bound CHF5074 molecules make 
hydrophobic and electrostatic interactions with some amino acids in the cavities: the 
latter are mediated by four polar contacts: the –COOH group of the ligand is close to 
the ε-amino group of Lys15 (2.48-3.15Å); the p-Cl atom of the di-chloro phenyl ring 
is close to the –OH group of Ser117 (3.8Å); the m-Cl atom interacts in a similar way 
and the fluorine atom interacts with the carbonyl oxygen of Ala109 (3.52Å). 
Measured distances are in agreement with values reported in literature. In addition, it 
is important to note that Ser117 and 117’ of B and B’ subunits interacts with the 
same residues of A and A’ subunits through hydrogen bond, stabilizing further 
tetrameric TTR. 
 
 
Figure 3.10: Surfaces (in lightblue) of the tetrameric TTR, comprising the two cavities in which 
ligand molecules (in stick model representation, coloured in magenta) are inserted. 
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3.1.2 Structure of TTR·Tafamidis 1:1 complex 
 
By screening a library of 2-arylbenzoxazoles, several potent and highly selective 
amyloidogenesis inhibitors were identified and, after obtaining high resolution 
crystal structures (1.3-1.5Å), structures of the various complexes were solved [111]. 
Tafamidis represents one of the most important benzoxazole derivatives: it was 
discovered by Kelly’s laboratory and developed by FoldRx Pharmaceuticals 
(acquired by Pfizer in 2010) [92]. It was demonstrated its capacity to slow the 
progression of FAP and, owing to this, it became the first drug to be approved for the 
treatment of FAP in 2011 [112].  
 
 
Figure 3.11: Schematic depiction of the inhibitor activity of a generic arylbenzoxazole derivative 
(stabilization of the TTR homotetramer, preventing amyloid fibrils formation) and magnification of 
the same inhibitor inside one of the two cavity, representing the X-ray crystallographic structure of the 
complex [111]. 
 
To date, TTR·Tafamidis complex is the highest-resolution structure solved (1.30Å) 
among the TTR·(ligand)2 structures [98]. In the context of the present work, the 
structure of the complex at 1.73Å was obtained from an equimolar mixture of protein 
and inhibitor, and not with a fivefold molar excess of Tafamidis as described by 
Bulawa et al. [98]. However, regardless of the stoichiometry ratio, Tafamidis was 
found in both the T4 binding sites and the good quality electron density map allowed 
for the unambiguous placement of the inhibitor in the cavities. As shown in Fig. 
3.12, there is no electron density corresponding to the carboxylate substituent, 
indicating that this part of the molecule is disordered in the crystal. Instead, the 
electron density associated with the more rigid benzoxazole moiety and the di-chloro 
phenyl ring is well defined. It is possible to confirm the binding mode by which the 
ligand enter the cavity: the benzoxazole ring and the 3,5-dichloro substituent of 
Tafamidis are located deep in the cavity and they establish interactions with all the 
HBPs, whereas the carboxylate end group is positioned at the entry port of the T4 
binding pocket. This results in water-mediated hydrogen bonds with Lys15/15’ and 
Glu54/54’.  
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Figure 3.12: View of the electron density map calculated with coefficients 2           and 
contoured at 2.0σ level only around the ligand (on the left in site B, on the right in site A), for 
Tafamidis bound to wt-TTR. 
 
As suggested by Bulawa et al. [98], because these low B-value waters are not 
conserved either in TTR and TTR·(ligand)2 complexes and because these hydrogen 
bonds are solvated, it appears unlikely that they represent the driving force for 
Tafamidis binding to TTR. 
 
 
Figure 3.13: Stereo view of the TTR·Tafamidis 1:1 complex showing the two Tafamidis molecules 
occupying both the hormone binding sites. 
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Figure 3.14: On the left, surface representation of the TTR·Tafamidis 1:1 complex, showing an 
overall view of the surface and one hormone binding site with the ligand inside it. On the right, Cα 
chain trace of TTR and the two Tafamidis molecules. 
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3.1.3 Structures of TTR·resv complexes  
The huge interest for resveratrol (3,5,4'-trihydroxy-trans-stilbene), a natural 
stilbenoid particularly found in berries, red wine and grape’s juice, is due to its 
beneficial effects on human health (at least on some heart diseases, cancers and 
metabolism). In addition, resveratrol (resv) significantly reduces TTR fibril 
formation and this is the reason why the stilbene derivative represents an excellent 
lead compound for the development of a new class of drugs against TTR amyloid 
diseases. In the present work, the structures of TTR·resv complexes were obtained 
either from an equimolar mixture and with a fourfold excess of the ligand. Moreover, 
the crystals used for data collection diffracted to a maximum resolution of 1.38Å and 
1.39Å and the structures attained from these crystals are the highest-resolution 
structures so far obtained. This has also allowed to define more details of the T4  
binding sites and to refine quite carefully the structure.  
 
 
Figure 3.15: Cartoon representation of the TTR·resv 1:1 complex showing the presence of the ligand 
only in one of the T4 binding sites (site B). 
 
With respect to the TTR·resv 1:1 complex, interpreting the electron density map is 
made easy thanks to the medium-high resolution and also the positioning of the 
ligand appears simple and unambiguous.  
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Figure 3.16: View of the electron density map of resveratrol in site B with coefficients 2           
and contoured at 2.0σ level. 
 
In particular, only in the site B the electron density of the ligand is clearly visible 
from the first stages of the refinement and, consequently, the structure was refined 
with a single resveratrol molecule. Slightly different appears the case of the 
TTR·resv complex obtained in the presence of an excess of the ligand: here, a well 
defined electron density of the ligand is visible in the site B but a less defined 
electron density can be noted in site A after several cycles of refinement. Including 
the second molecule of resveratrol in site A and performing a refinement shows that 
ligand atoms in site A are characterized by higher B-factors and lower occupancy, as 
expected. Both structures, however, show the same binding mode for the ligand: the 
p-hydroxyl group is positioned at the entry port of the T4 binding pocket, whereas the 
other two –OH groups are located deep in the cavity.  
Nevertheless, comparing this result with the structure reported in 2000 by Klabunde 
et al. [88] revealed an exactly opposite binding mode (Fig. 3.17).  
 
Figure 3.17: Stick model of the resv bound to the hormone binding site. Electron density map is 
shown in cyan chicken wire around both the conformations of the ligand (in yellow and white) [88]. 
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These two conflicting results may have at least two explanations: in primis, the 
structure reported in the article quoted above was obtained at a lower resolution 
(1.9Å) and it is possible that there has been, during refinement procedure, a wrong 
positioning of resveratrol in the cavity, due to lower definition of the electron density 
map. In fact, the electron density in Figure 3.17 represents the result of several cycles 
of refinement and so it contains a bias due to the original position of the model, 
because during the optimization procedure phases (hopefully) gradually improve and 
this is reflected in the quality of the electron density map, which also improves. In 
any case, there is probably a combined effect taking into account a second 
explanation: unlike the crystals obtained for the present study, Klabunde and co-
workers have prepared the crystals by soaking. Growing crystals from a mixed 
solution is clearly different from soaking, in which a pre-existing crystal of TTR is 
placed in a solution containing the ligand at a precise concentration (Klabunde et al. 
used a tenfold molar excess of resveratrol to ensure full saturation of both binding 
sites). When transthyretin is in solution, it has more degrees of freedom and it is 
characterized by a greater flexibility: as a consequence, when an hypothetical ligand 
molecule approaches one of the cavity cannot only enter inside it but can also sit in 
the best conformation, eventually after a series of structural adjustments in order to 
find the minimum energy conformation. With the soaking method, the molecules of 
TTR are already packaged inside the crystal lattice in a rigid manner and the entry of 
the ligand, obviously, is not as free as in the previous case because of additional 
restraints imposed by the lattice forces. In other words, in solution the structure of 
the uncomplexed TTR is unaffected by the interaction of symmetry-related 
molecules present in the crystal lattice. 
Fig. 3.18 is a representation of the main residues involved in the interaction between 
resveratrol in site B. In spite of the opposite findings [88], some features remains 
probably unaffected: also with an opposite binding mode, ligand-protein interactions 
remain likely dominated by non-polar contacts mediated by the stilbene moiety, 
which is stacked between the hydrophobic side chains of Lys15, Leu17, Ala108, 
Leu110, Ser117, Thr119 and Val121. It is expected that changes in the interaction 
between resveratrol and the residues lining the cavity involve the hydroxyl groups of 
the ligand and the amino acids that are present deep in the cavity and at the entry of 
it. As already discussed, Klabunde et al. reported the structure of the complex in 
which the p–OH of the distal phenyl ring is deeply bound in the cavity and they 
argued that this causes the displacement of water molecules positioned in HBP3 of 
the apo-form. This, in turn, is responsible for the formation of a tight hydrogen bond 
between the p–OH of resv and the Oγ atom of Ser117 (2.6Å). With an opposite 
binding mode, it is possible that hydrogen bond interactions are strengthened: this is 
because in the new situation there are two hydroxyl groups involved and the 
measured distances ranges from 1.8Å to 3.5Å. The hydrogen bonds are not too long 
and remain sufficient strong to justify the high affinity of resv.  
 45 
 
Secondly, they reported a structure in which the two hydroxyl groups on the second 
phenyl ring are located at the entry of the binding cavity and they also stated the 
formation of hydrogen bonds with ordered water molecules. There are no reasons 
why this should change with an opposite binding mode; however, it has also to be 
considered that the p–OH can establish (weak) hydrogen bonding interactions with 
the side chain carboxylic groups of Glu54 and 54’.  
 
 
Figure 3.18: At the top: hormone binding site structure of the TTR·resv 1:1 complex, showing the 
relevant residues involved in the interaction with the ligand (the ligand shows Van der Waals 
interactions with several side chain residues). The stilbene scaffold is sandwiched between two 
adjacent protein subunits filling the central parts of the channel. At the bottom: detailed views of some 
relevant interactions involving the hydroxyl groups of resv with Ser and Glu residues inside the 
cavity. 
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3.1.4 Structures of TTR·T4 1:1 and mixed TTR·T4·resv complexes  
All structures published so far and relative to the TTR·T4 complex were obtained 
from crystals grown in the presence of an excess (usually a 10-fold molar excess) of 
thyroxine and, in these cases, it was observed that both the binding pockets are 
saturated with T4. In this context, it is useful wondering if the T4 binding sites remain 
fully saturated even in the presence of an equimolar quantity of the ligand and, to 
answer this question, crystals of the complex TTR·T4 1:1 were prepared.  
 
  
Figure 3.19: Stereo view of the TTR·T4 1:1 complex showing the two thyroxine molecules occupying 
both the hormone binding sites. 
 
The subsequent structure refinement revealed that, also in this case, thyroxine 
occupies both sites on the TTR tetramer: however, positioning it in the two cavities 
does not appear an easy task. This is so because of the absence of electron density 
relative to the ligand and exploiting anomalous scattering originated by the four 
iodine atoms is the only way to try to correctly locate the T4 molecules in the 
structure. For this purpose, starting from the anomalous Bijvoet pair structure factors 
F
+
 and F
–
 as input data, the map coefficients were generated and the related 
anomalous difference map. This map was used to localize the dispersive iodine 
atoms and what emerges is that the anomalous signal is present in both the sites. In 
particular, up to 12σ for site B and up to 14σ for site A, all the iodine atoms are 
visible: above this level, only half of the dispersive atoms appear in the anomalous 
difference map.  
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In agreement with the structures already solved, the ligand interact with the cavities 
in the so called forward binding mode, that is the α-carboxylate and the α-amino 
groups of T4 occupy the outer binding pocket.  
 
 
 
Figure 3.20: View of the anomalous difference map around the ligand with coefficients 2           
and contoured at 2.0σ level (on the top in site B, on the bottom in site A), for TTR·T4 1:1. 
 
Until now, structures of complexes between TTR and different small molecules were 
obtained by co-crystallization with a single ligand: however, it is interesting to 
investigate what happens when transthyretin is crystallized in the presence of, at 
least, two different molecules. For this aim, TTR was crystallized in the presence of 
either resveratrol and T4 and the structure of the relative complex TTR·T4·resv was 
obtained. Inspection of the structure so obtained reveals that both the ligands are 
present in the two binding sites but with different occupancy values: it is worth 
noting that the crystallographic model reflects the average structure of all unit cells 
 48 
 
during the experiment time. This means that if there are different subpopulations of 
TTR molecules (over the total ensemble) that are bound only to resv, or only to T4, 
or both, or anything else, the final crystal structure reflects this heterogeneity. In 
other words, in the case (and this is it) that not all unit cells in the crystal are 
perfectly identical (in terms of chemical composition, relative orientation of the 
molecules etc.) the crystal structure is a spatial average, and not a snapshot of a 
single and arbitrarily subpopulation. Looking at the electron density map, and 
making use of the anomalous difference map, resveratrol was found mainly in site B 
whilst T4 particularly in site A. In site A, all the four iodine atoms are visible up to 
9σ: above this level of r.m.s.d., only half of the atoms remain visible (and disappear 
at 18σ, whereas in site B the anomalous signal vanish at 12σ). 
 
 
Figure 3.21: On the top, stereo view of the electron density maps (in grey) with coefficients 2      
     and contoured at 2.0σ level around resveratrol in site B and T4 in site A. On the bottom, stereo 
view of the anomalous difference maps (in red) with coefficients 2           and contoured at 2.0σ 
level either in site A and B. Both figures are relative to the TTR·T4·resv complex. Both 
representations depict TTR ligands as they are bound in the two symmetry-related binding modes. 
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Figure 3.22: Overall view of the surface of the TTR·T4·resv complex, along with cartoon 
representation of the monomers, with resveratrol and T4 occupying the hormone binding sites. 
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3.1.5 Superposition Analysis 
 
There are several cases in which the binding event of a molecule to a protein is 
responsible for large conformational changes in the overall structure of the 
macromolecule: in nature, for example, large conformational modifications of 
receptors caused by binding of substrates, inhibitors or activators determines the 
functional state of the receptor and is one of the way to induce signal transmission. 
This principle represents also the mechanisms of action of many drugs that, upon 
binding to the target receptor, are able to produce a biological and physiological 
response. With this premise, it is useful and interesting to evaluate the impact that 
TTR ligands have on the overall structure of the protein after they have entered the 
hormone binding site(s). The alpha-carbon superposition of the structure of wt-TTR 
with the structures of all the six complexes was carried out using the structural 
alignment tool implemented in MacPyMOL. It performs a sequence alignment 
followed by a structural superposition, and then carries out some cycles of 
refinement in order to reject structural outliers found during the fit. In the attempt to 
align the two structures it minimize the r.m.s.d. for the corresponding coordinates of 
the structurally equivalent alpha carbons. This works very well for homologous 
structures, as for the alignment of TTR complexed and uncomplexed, and makes use 
only of the Cα positions for simplicity and efficiency. The output of a structural 
alignment are a superposition of the atomic coordinate sets and the minimal root 
mean square deviation between the structures, which indicates their difference.  
Evaluation of the overall protein movements in the TTR tetramer induced by ligand 
binding showed no significant changes in the hormone binding sites, with an r.m.s.d. 
ranging from 0.103Å to 0.244Å (see Table 3.1). For instance, in Fig. 3.23 is reported 
the Cα superposition between wt-TTR and TTR·CHF5074 1:1 complex from which 
it can be observed the minimal differences in the Cα positions after ligand binding.  
Table 3.1: R.m.s.d. values obtained from Cα superposition between wt-TTR and the six complexes. 
TTR·ligand complex r.m.s.d. (Å) 
TTR·CHF5074 1:1 0.244 
TTR·Tafamidis 1:1 0.206 
TTR·resv 1:1 0.125 
TTR·resv excess 0.115 
TTR·T4 1:1 0.108 
TTR·T4·resv 0.103 
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Figure 3.23: Superposition of Cα traces of wt-TTR (orange) and TTR·CHF5074 1:1 complex 
(coloured by monomers); for this case, r.m.s.d. is 0.244Å.  
  
As anticipated in Paragraph 1.8.5, the same superposition analysis has proven to be a 
useful tool to assess the effectiveness of the therapeutic strategy based on the use of 
TTR stabilizers, particularly CHF5074 and Diflunisal [99]. The study focused on the 
amyloidogenic variant I84S TTR, that undergoes large conformational changes at 
moderately acidic pH. The superposition of wt-TTR·CHF5074 at neutral pH on the 
complex I84S TTR·CHF5074 (or with Diflunisal) at acidic pH gives r.m.s.d. of 
0.34Å and 0.29Å, respectively. A similar r.m.s.d. was obtained after the 
superposition with the structure of wt-TTR, whereas the same comparison between 
I84S TTR and I84S TTR·CHF5074 at low pH provides values of 0.49 and 2.12Å for 
monomers A and B, respectively. The comparison between these structures showed 
that the structure of the complex I84S TTR·CHF5074 remains well preserved, even 
at acidic pH: CHF5074 stabilizes the amyloidogenic TTR mutant converting it to that 
typical of wt-TTR at neutral pH. 
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3.1.6 Conclusions  
 
Medium-high resolution data sets were processed and analyzed, allowing to obtain 
good quality structural models of all the TTR·ligand complexes. All the complexes 
displayed the presence of the ligand(s) in one or both sites. In the complexes with 1:1 
stoichiometry between TTR and CHF5074, Tafamidis and T4, it was observed that 
ligands saturate both sites (A and B). In the case of TTR·resv 1:1 complex, 
resveratrol only occupies site B, whereas for the same complex obtained in the 
presence of an excess of the ligand even a partial occupancy of site A was noted. For 
the mixed complex, resveratrol shows a preference for site B and T4 for site A. From 
these observations it is possible to state that, in some complexes, ligands exhibit a 
preference for one binding sites relative to the other. Localization and placement of 
ligands in the electron density maps was relatively straightforward, with the 
exception of the complexes of TTR with T4. In these cases, the exploitation of the 
anomalous scattering allows the localization of iodine atoms and the ligand has been 
introduced in the structure based solely on this information. For the other molecules 
(resveratrol, Tafamidis and CHF5074), the ligand electron density inside the 
hormone binding sites was good enough from the first refinement cycles to allow the 
unambiguous positioning inside the cavity. All these molecules have a rigid moiety 
with some flexible groups: despite the poor (or missing) electron density for the 
latter, the stiffer aromatic portion shows in good details the contours of the various 
ligands.  
In addition, as introduced before, ligand electron density maps for the complexes 
involved in the study seems to confirm the preference for resveratrol, T4 and 
CHF5074 for one site over the other, i.e. the asymmetric ligand binding to 
transthyretin observed in recent articles. It is worth noting that the crystallization 
method adopted has a strong influence on the possibility to observe asymmetric 
ligand binding: relying on what appears recently in literature [69], molecular 
dynamics simulations suggest a certain degree of flexibility of TTR in solution. The 
plasticity of some chains causes continuous fluctuations of the protein so that the 
binding sites became alternatively larger and smaller (compared to the size observed 
in the crystal structure). In this situation, the first ligand molecule that approaches the 
protein will enter in the larger cavity and, if present in excess, a second molecule of 
ligand must fit to the remaining site, temporarily smaller: this explanation can justify 
the different affinity constants measured for both sites on TTR. However, the 
simulations provide a realistic picture only if they reflect the behaviour of TTR in 
solution and the question that arises is whether these differences in ligand preference 
are already present in solution or not. In the present work, crystal complexes were 
obtained by co-crystallization, i.e. the different complexes were formed in solution 
and, only when supersaturation was reached, they crystallize: this means that any 
influence of crystal packing on the formation of the complexes was avoided. 
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Instead, in the soaking method ligand molecules have to enter in the cavities on TTR 
when the protein is already embedded in the crystal lattice, locked by lattice forces. 
In this case, protein has less degrees of freedom and the two binding sites are more 
similar than in solution, in which TTR can undergoes fluctuations. Indeed, 
asymmetric ligand binding is not detectable if the complex is obtained by soaking in 
presence of a ligand excess. After these considerations, it can be only speculated that 
differences in the preference of some ligands for one site over the other were already 
present in solution, but further investigations are required in order to fully address 
this point. 
Apart from the complex between TTR and Tafamidis, the co-crystals relative to all 
the other complexes diffracted to a maximum resolution that is better if compared 
with the structures so far reported in literature. In addition, the coordinate and the 
structure factors of some complexes will be deposited in the Protein Data Bank 
(PDB). In all cases, after an alpha-carbon superposition analysis between wt-TTR 
and the different complexes, it was established that ligand binding does not alter in 
any appreciable way the positions of the chains and, as a consequence, the structure 
of the tetramer. Although until now only TTR complexes with an excess of the 
ligand have been studied, in the present work also four complexes obtained with an 
equimolar amount of ligand have been taken into account. This was done in order to 
study the ligand affinity and the saturation of the T4 binding sites in the presence of 
different stoichiometries between TTR and small molecules. Moreover, a novel 
mixed complex with two different ligands, thyroxine and resveratrol, was 
crystallized and its structure determined. Such mixed complexes may be promising 
candidates for an even more effective treatments of TTR amyloidosis: administering 
a cocktail of two ligands, each of which exhibits a preferential binding to one site 
relative to the other, it is possible to achieve the full saturation of the TTR tetramer, 
favouring its stabilization. Moreover, the therapeutic approach based on the use of 
small molecules in the treatment of TTR amyloidosis has a more general 
applicability. Indeed, the use of small molecules as drugs is currently under 
investigation in the treatment of other amyloidosis, as ALS (Amyotrophic Lateral 
Sclerosis) or in lysozyme amyloidosis.  
X-ray crystallography can play a crucial role in this process, as it can provides more 
insights into the structure of the binding cavities in which the interaction between 
some key residues and the ligand takes place. Despite the possibility to capture 
intermediates or end points during protein misfolding, which is a dynamic process, 
crystal structures determined by X-rays provides static snapshots: as a consequence, 
biological, biochemical and biophysical studies are also valuable and necessary. 
With the convergence of all these results, in a not too distant future it will be possible 
to rationally designed more effective inhibitors for the TTR amyloid diseases. 
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Part II 
 
HtrA protease 
In the following Introduction to Part II, HtrA is described: the main features of 
prokaryotic and eukaryotic HtrA proteases are outlined, including their structure and 
biological roles, focusing the attention mainly on the implication for virulence and 
pathogenesis of Campylobacter strains. 
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2.1 HtrA Proteases  
2.1.1 Helicobacter pylori 
Helicobacter pylori (Hp) is a Gram negative bacterium specialized in the 
colonization of human stomach: it colonizes more than 50% of the human 
population, but most infected people are asymptomatic and only a minority (15-20%) 
develop some gastroduodenal pathologies (stomach and duodenal ulcers, 
adenocarcinomas and stomach lymphomas). To survive in the stomach, it has 
developed several strategies: firstly, Hp synthesizes different ureases to buffer the 
acidic pH typical of this environment [113]. To do this, Hp used several genes, 
through a seven-gene cluster composed of genes A, B, I, E, F, G, H, corresponding to 
the respective ureases. These enzymes utilize urea (physiologically present in the 
stomach) as substrate to produce, by hydrolysis, ammonia and CO2: in this way, Hp 
can neutralize the acidic pH, even if it is not an acidophile. Urease was the first Hp 
enzyme crystallized, in addition to being the first enzyme shown to contain nickel 
[114]. It is a dodecamer of six UreA and six UreB subunits and it is a virulence 
factor with a prominent role in the pathogenesis of Hp-associated diseases: Hp urease 
might cause damage to the host cells through the production of cytotoxic ammonia 
[115] and it was shown that urease defective Hp mutants cannot colonize the 
stomach [116]. In order to survive in the stomach, however, Hp elaborates other 
mechanisms, for example the use of flagella: with these appendages, Hp travels 
across the viscous mucus film and adhere to the host cells. As source of locomotion, 
flagella are responsible for Hp motility and it has been demonstrated that the degree 
of motility of Hp strains correlates with the degree of infectivity [117] [118]. Also its 
typical helicoidal shape allows Hp to cross the thick layer of mucus [113]. Virulence 
factors other than ureases exist in Hp: these molecules contribute to the pathogenicity 
and the main are: adhesins (three Hop proteins in particular) and outer membrane 
proteins, VacA and CagA [119] [120]. Many bacterial factors mediate the adhesion 
of Hp to the gastric epithelium (also many polysaccharides), such as the proteins 
BabA (HopS), OipA (HopH) and SabA (HopP): cell adhesion is an essential 
requirement in Hp colonization and only after this step the pathogen can injects into 
the host cells different toxins as CagA (for “Cytotoxin-associated gene A”). CagA is 
a highly immunogenic protein encoded by the CagA gene, that is present in 
approximately 50% to 70% of Hp strains and is a marker for the presence of a 40kb 
genomic Pathogenicity Islands (PAI) that encodes between 27 and 31 proteins. 
Strains carrying the cagPAI are referred to as CagA
+
, as they are commonly 
identified in patients by their potential to induce significant antibody against CagA 
[120]. In Hp, the Cag Type IV secretion apparatus, encoded by cagPAI and 
composed of a pilus-like structure, can mediate the injection of CagA into the target 
cells: the translocated CagA proteins will interfere with the physiological signal 
transduction and cause pathological cellular response (increased cell proliferation, 
motility, apoptosis and morphological change). In fact, once in the cell, CagA is 
phosphorylated at Tyr residues in EPIYA motifs by Src family kinases and then 
interacts with a range of host signalling molecules such as the tyrosine phosphatase 
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SHP-2, which results in morphological changes in the epithelial cells [121] [122]. 
The cagPAI also affects the immune response and the interaction between the type 
IV secretion apparatus and the host cell, resulting in the induction of 
proinflammatory cytokines. CagA has been associated with severe gastritis and thus 
with a higher risk for ulcer disease, atrophic gastritis and gastric cancer [123]. After 
CagA, VacA (“Vacuolating cytotoxin A”) is the second most extensively studied Hp 
virulence factor (approximately 50% of all Hp strains secrete VacA) with high 
immunogenicity and with an important role in the pathogenesis of both peptic 
ulceration and gastric cancer. It induces massive vacuolization in epithelial cells in 
vitro [124] [125]; as other bacterial toxins, it is recognized as a multifunctional 
protein that can have pleiotropic effects on mammalian cells and tissues. Indeed, it is 
involved in a series of effects including membrane channel formation, induction of 
apoptosis, immune modulation and increased transcellular permeability [126]. 
 
2.1.2 Campylobacter jejuni  
As Hp, Campylobacter jejuni (Cj) is a microaerophilic, Gram negative, flagellate 
bacterium, with a curved or spiral shape [127]. Gram negative bacteria of the genus 
Campylobacter and of related genera, Cj in particular, frequently colonize the 
gastrointestinal tracts of mammals, including humans, and birds [128]. Typical 
reservoir includes not only wild birds but also insects, poultry (whose intestines are 
easily colonized with Cj), cattle, farm workers, drinking water and many food of 
animal origin such as milk [129]. Cj has been recognized as an important human 
pathogen, usually causing diarrhoea, fever and abdominal cramps, but other 
symptoms may occur [130]. Although the cornerstone treatment for Cj enteritis 
consist of maintenance of hydration and electrolyte balance without antibiotics, there 
are specific clinical circumstances in which antibiotics should be used and local 
complications can arise [131]. The most important post-infections complication of Cj 
is the Guillain-Barré syndrome (GBS) [132] [133]. Outbreak have been associated 
with drinking raw milk, contaminated water, consumption of undercooked poultry 
and mishandling of raw poultry, which constitute major risk factors for human 
campylobacteriosis [129]. Infection with Cj occurs more frequently than do 
infections caused by Salmonella species, Shigella species and E. coli and, although 
14 species of Campylobacter have been identified, more than 99% of reported 
infections with Campylobacter in the United States are with Cj [131]. During the 
years, different determinants of Cj pathogenicity have been identified, in particular: 
chemotaxis, motility (Campylobacter species are motile by means of unipolar or 
bipolar flagellae), adhesion, cellular invasion, iron acquisition, epithelial 
translocation, toxins and lipopolysaccharide (LPS), the latter being a virulence 
determinant in many species of Gram negative bacteria. Chemotaxis, mobility and 
flagella are required for attachment and colonization of the gut epithelium. Once 
colonization occurs, iron acquisition, host cell invasion, toxin production, 
inflammation and active secretion come into play [127] [129].  
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However, Cj lacks the virulence associated secretion systems, such as type III and 
type IV secretion systems, possessed by other enteric pathogen: it was demonstrated 
that, as many bacterial pathogens, Cj utilizes outer membrane vesicles (OMVs) for 
delivery of virulence factors into host cells [134]. Although OMVs from Cj were 
identified nearly 30 years ago, only recently their role in the pathogenesis become 
clear with the demonstration that the Cytolethal Distending Toxin (CDT) was 
delivered within OMVs in Cj [135]. To understand and clarify the behaviour of Cj, in 
2000 for the first time the complete genome of Cj NCTC11168 has been sequenced 
[136]: 
 
 
Figure 2.1: Circular representation of the Cj genome. Circles in dark and pale green represent coding 
sequences transcribed in the clockwise and anticlockwise direction, respectively. The black circle 
shows the positions of hypervariable sequences, while circles in dark (clockwise) and pale red 
(anticlockwise) show genes involved in the production of surface structures. In orange, the histogram 
that shows the similarity of each gene to its Hp orthologue, where present (height of the bar and 
intensity of the colours are proportional to the degree of similarity) ([136]). 
 
Cj has a circular chromosome of 1,641,481 bp which is predicted to encode 1654 
proteins (referred as coding sequences, CDSs) and 54 stable RNA species: it is 
characterized by an average gene length of 948bp and because 94.3% of the genome 
codes for proteins, this is the densest bacterial genome sequenced to date. Functional 
information could be deduced for 77.8% of the total 1654 CDSs, whereas the 
remaining matched genes had no database match, revealing an unusually low number 
of unknowns. Some surprising features emerging from the study are: the almost 
complete lack of repetitive DNA sequences, the absence of any functional inserted 
sequence elements, transposons, retrons or prophages in the genome and a little 
organization of genes into operons or clusters. The most striking finding was the 
presence of hypervariable sequences, because these tracts might be important in the 
survival strategy of Cj.  
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Hypervariable sequences were found in genes responsible for lipooligosaccharide 
(LOS) synthesis, extracellular polysaccharide (EP) synthesis and flagellar 
modification. Another strangeness is that Cj has 3 sets of genes involved in sialic 
acid biosynthesis: this is an uncommon component of bacterial surface structures and 
it may be important in GBS. On the other hand, expected results include finding of 
some toxin genes (such as CDT gene), several type 4 pilus related genes involved in 
chemotaxis and that the Cj genome encodes five major iron acquisition systems. 
Although Hp and Cj share many biological properties, there are genes present in Hp 
but absent in Cj as urease operon, nickel transport system, vacuolating toxin and the 
cagPAI, and these features are expected since Hp lives in the stomach, a unique 
niche. Following the same reasoning, that is the presence of Cj in a more diverse 
range of ecological niche than Hp, it is not surprising the presence of a broader 
repertoire of regulatory systems in Cj (mainly of the two component regulatory 
family).  
 
2.1.3 HtrA proteases 
The accumulation of damaged proteins (fragmented, misfolded or mislocalized) 
represents a serious hazard to the cell because it can result in the 
accumulation/aggregation of proteins, leading to amyloid diseases or, in general, 
hampering important biological processes. To reduce the amount of unfolded or 
aggregated proteins, cells have developed a system of proteases and chaperones with 
the aim to remove hazard polypeptides and to assist the correct folding and assembly 
of proteins, respectively. Proteases not only are implicated in housecleaning 
functions by degrading damaged proteins but, particularly in higher organisms, play 
important roles being involved in cell growth, apoptosis and others [137] [138]. This 
class of proteins are classified in the MEROPS database 
(http://merops.sanger.ac.uk/), which include also their substrates and inhibitors. 
Among these, HtrA is a protein of increasing interest since it is involved in numerous 
and different physiological processes: it was firstly identified in E. coli by Lipinska 
in 1988 while he was working on htrA null mutants. He observed that all mutants do 
not grow at high temperatures, since the name: High temperature requirement A 
[139], or in consideration of the null mutant phenotypes it was also referred to as 
DegP for: Degradation of periplasmic proteins [140]. However, DegP is not 
synonymous of HtrA because this acronym indicates only one of the three HtrA in E. 
coli. HtrA represents the first well-studied protein quality control factor that acts in 
an ATP-indipendent manner; it belongs to the Ser proteases family but it displays 
both functions, as protease and chaperone. It is widely conserved in single and 
multicellular organisms [141]: hundreds of different HtrA have been detected in 
various sequenced genomes, comprising those of microorganisms (both Gram 
negative and Gram positive bacteria), fungi, plants, frogs, birds, fish and mammals, 
including Homo sapiens.  
 60 
 
In addition, in many cases the same organism displays more than one HtrA [138] 
[142] [143] with different cellular localization and functions: a proof of this comes 
from the consideration that E. coli, cyanobacteria, Arabidopsis thaliana and humans 
have, respectively, three, two to five, sixteen and four HtrAs.  
 
2.1.3.1 Prokaryotic HtrAs 
With regard to prokaryotic HtrAs, research has been focused on HtrA homologues 
from E. coli: here, the three family members DegP, DegS and DegQ have been 
identified as actors in the protein quality control in the periplasmatic space [138]. 
DegS is a purely regulatory protease and DegQ is highly homologue to DegP and 
might therefore perform similar functions [144]. Mature DegP from E. coli has 448 
residues of which His105, Asp135 and Ser210 form the catalytic triad [138]; it 
combines proteolytic and chaperone activities and, whereas in the resting state it is 
an hexamer, higher oligomeric structures of 12-, 15-, 18- and 24-mers are observed 
following activation [145] [146] [147] [148]. Given that the basic building block for 
all HtrAs is the homotrimer, the transition to protease-active oligomeric forms 
represents a simple and effective mechanism for controlling access to the proteolytic 
sites of DegP (and not only). The switching from an inactive, low molecular mass 
oligomer into a substrate degrading, higher order oligomer allows for precise 
regulation of protease activity [137]. Evidences for the same mechanism in other 
HtrA have been suggested, but in certain cases a different regulation of the 
proteolytic activity was shown [149] [150]. Despite it has both activities, a 
distinctive properties of DegP is the temperature-dependent switch from chaperone 
to protease function: the proteolytic activity is negligible below 20°C, but over 30°C 
it rapidly increases in a non linear fashion. The chaperone function dominates at low 
temperatures, while the proteolytic activity manifests itself at elevated temperatures: 
this behaviour, from a protein-folding to a protein-digesting machine, is plausible 
since at higher temperatures proteins might be too badly damaged to be refolded and 
have to be removed. At low temperatures, protein repair appears to be more efficient 
[151]. From the above statements, it is straightforward to infer that DegP is an heat 
shock protein, that is a protein whose expression is increased in response to exposure 
to stressful conditions such as temperature, UV light and increased oxidative or 
osmotic stress: in other words, they counteract protein folding stress. However, 
unlike other heat shock proteases, the DegP activity is largely independent of 
cofactors as ATP, pH, reducing agents and divalent cations [138]. It is well 
established that prokaryotic HtrAs are involved in the heat shock response and 
contribute to tolerance of harsh conditions [152] [153] [154] [155] [156], but they 
contribute also to bacterial pathogenicity, e.g. supporting biofilm formation [157], 
secretion of virulence factors [158] and remodelling of the cell-cell contacts within 
the host organism [159]. In any case, other bacterial proteases also contribute to 
pathogenesis, revealing a more general trend [160] [161].  
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It has been demonstrated that HtrAs contribute to virulence in a number of bacterial 
species [162] [163] [164] [165] [166] [167] [168] [169] [170] [171]. Another 
example comes from Hp, whose HtrA is secreted into the medium to cleave E-
cadherin that represents a mammalian cell surface protein that has essential function 
in cell adhesion. In agreement with recent results [159], this reveals how Hp uses 
HtrA as a bacterial proteases in a coordinate manner with other injected effector 
proteins, such as CagA. As a consequence of the cleavage, the epithelial barrier is 
destroyed allowing the persistent colonization, nutrition and pathogenesis. Probably, 
this finding might unveil a general bacterial strategy and HtrA could therefore be a 
promising candidate for therapeutic intervention.   
 
2.1.3.2 Eukaryotic HtrAs 
Although eukaryotic HtrAs are less well characterized than prokaryotic ones, in the 
last few years crystal structures of HtrA1 and HtrA2 (also termed Omi) from humans 
and Deg1 from A. thaliana have been solved. Eukaryotic HtrAs displays additional 
functions to those seen until now for their prokaryotic counterparts because they are 
also involved in photosynthesis, cell proliferation, apoptosis, cell development and 
ageing processes; in addition, they contribute to a number of severe medical 
conditions such as arthritis, cancer, Parkinson and Alzheimer’s disease [172]. For 
example, in A. thaliana, five of the 16 HtrAs present (Deg1, Deg2, Deg5, Deg7 and 
Deg8), are located in chloroplasts [142] [173]: among them, the best characterized is 
Deg1 that performs the typical dual function, acting as a chaperone in the assembly 
of PSII and as protease in the degradation of damaged reaction centres [142] [174] 
[175] [176]. Studies carried out on Deg1 in plants converge towards a model for its 
function in vivo, according to which Deg1 adopts a monomeric resting state in the 
dark that turns into a proteolitycally active hexamer upon illumination. This is 
because, in the absence of light, the need for degradation of photosystem components 
is minimal but, in the presence of strong radiation, the pH of the thylakoid lumen 
drops and there is an urgent need to remove photosystem proteins damaged by 
oxidation. So, Deg1 is specifically activated under light-stress conditions and the 
transition to an higher oligomeric state allows to carry out its function [137] [172]. 
Despite the important roles that HtrAs cover in plants, human HtrAs (hHtrA) receive 
most of the attention owing to their involvement in key processes: for example, 
hHtrA1, the best characterized family members together with hHtrA2 and 
ubiquitously expressed in all tissues, is implicated in cell proliferation, tumour 
suppression, processing of numerous secreted proteins, arthritis, cancer, familial 
ischemic cerebral small-vessel disease, age-related macular degeneration and 
Alzheimer’s disease [177] [178] [179] [180] [181]. In more detail, the loss of HtrA1 
correlates with decreased sensitivity to anticancer drugs and increased cell migration 
[178] [182] [183]; in addition, over-expression of HtrA1 inhibited proliferation in 
vitro and tumour growth in vivo [184] suggesting that, in combination with the 
precedent observations, HtrA1 might function as tumour suppressor.  
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Another human HtrA, hHtrA2/Omi, promotes cell death, might function as a protein 
quality control factor in mitochondria similar to prokaryotic HtrAs in the periplasmic 
space [172] and appears to be implicated in neurodegenerative diseases [185]. 
 
2.1.3.3 Structural aspects of HtrA proteins 
As seen before, eukaryotic HtrAs display additional set of functions: despite this, 
HtrA proteins share a common modular domain architecture based on a catalytic 
protease domain and one or two C-terminal PDZ domains, overall arranged in the 
same basic oligomerization mode, that is a funnel-shape trimer. The Ser protease 
domain is structurally well conserved in all HtrAs (average r.m.s.d. ~ 0.6Å) [186] 
and it displays the canonical trypsin fold (two β-barrel lobes with additional α-helices 
attached); it forms the central core of the trimer and the catalytic portion is 
constituted by the triad Ser-His-Asp. 
 
Figure 2.2: a) Top view of the trimeric building block of HtrA proteases in which the protease 
domains are located in the centre and the PDZ domains protrude outwards and b) side view of the 
same trimer ([137]). 
In HtrA proteins, interaction between three protease domains are responsible for the 
trimer formation; linked to the central core, PDZ domains extend themselves 
outwards [137] [172]. PDZ domains are highly abundant being present in all 
kingdoms of life, are composed of 80-100 amino acids and represent one of the most 
common protein-protein interaction domains in humans. In truth, it was observed that 
they are scarce in unicellular organisms and this has led to the hypothesis that PDZ 
domains have evolved to facilitate intercellular signalling in multicellular organisms 
[187]. The canonical structure consists of five to six β-strands (β1-β6) and two α-
helices (α1-α2) [188]. The observed dissociation constants are consistent with their 
role as malleable protein-protein interaction modules, which can bind to and 
dissociate from their target ligands on a fast time scale [189]. They often recognize 
short residues motifs (preferentially three to four residues) at the C-termini of target 
proteins [137] [190].  
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Compared to the protease domain, PDZ domains are structurally less conserved 
(average r.m.s.d. ~ 1.2Å), consistent with the variety of roles that they play in 
different HtrA family members [172]. 
 
 
Figure 2.3: PDZ domain: β-strands are coloured orange, α-helices in yellow and the extra segment in 
red ([138]). 
 
Current research on HtrA proteins, however, could have important implications, for 
example in protein production: co-overexpression of the protein of interest with an 
HtrA with dual function can improve the yield of the recombinant product owing to 
the chaperone activity (that could assist the proper correct folding) and to the 
protease activity (important in removing misfolded proteins). Another beneficial 
effect can be derived from the temperature-dependent switch shown by DegP. 
Furthermore, DegP and DegS could become the target for antimicrobials (thanks to 
the Human Genome Project, about 14% of human proteases known nowadays are 
under investigation as potential drug targets) [138] [191]. Also, hHtrA1 and hHtrA2 
could be explored as drug targets in osteoarthritis, cancer and aging [138]. 
 
2.1.3.4 Cj and roles of its HtrA 
As all the other Gram-negative bacteria, also cells of Cj are composed of a 
periplasmic space between the Outer and the Inner Membrane. Since the former 
allows free diffusion of small molecules, periplasmic proteins are more highly 
exposed to fluctuating and stressful environmental conditions than cytoplasmatic 
proteins, hence the need to make use of chaperons and proteases. This is exactly 
what happens in Cj, which depends on periplasmic HtrA (and other proteins) to 
counteract temperature and pH fluctuations, osmotic stress and elevated O2 tensions 
during its transmission to human host. In Cj, HtrA has at least two functions: it 
confers tolerance to environmental stress and it is implicated in its virulence. With 
regard to the first function, initial studies [192] have shown that the tolerance to 
stressful conditions depends on HtrA, without wondering if this behaviour might 
depend more on a function that on the other. Successively, several studies have 
demonstrated that resistance relies mainly on the chaperone activity.  
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Using a Cj mutant lacking only the protease activity of HtrA, it was shown that HtrA 
chaperone activity is sufficient for growth at high temperatures or under oxidative 
stress, whereas the HtrA protease activity is essential only under conditions close to 
the growth limit of Cj [193]. In regard to the second function, HtrA displays a role in 
the virulence of Cj through, at least, three mechanisms.  
In primis, HtrA of Cj is required for efficient binding to the host epithelial cells. By 
comparing an htrA mutant lacking protease activity, but retaining chaperone activity, 
with a ΔhtrA mutant and the wt strain, it was seen that binding to epithelial cells was 
facilitated mainly by HtrA chaperone activity that may be involved in folding of 
outer membrane adhesins [194]. Other studies, using tissue cultures of human 
epithelial cells, found that the htrA mutant adhered to and invaded human epithelial 
cells with a decreased frequency compared to the wt strain [192]. Secondly, as seen 
also for Hp, E. coli and Shigella, the HtrA of Cj cleaves E-cadherin on host cells. It 
was established that HtrA mediated E-cadherin cleavage is a prevalent novel 
pathogenic mechanism exploited by multiple Gram negative bacteria representing an 
attractive potential target for therapeutic intervention to tackle bacterial infections 
[195]. HtrA deletion in Cj led to severe defects not only in E-cadherin cleavage but 
also in other mechanisms such as cellular transmigration (i.e. the migration of cells 
across a barrier, for example a cell layer), representing the third possible mechanism 
of virulence [196]. However, despite the progress that has been made in recent years 
in light of potential important applications, there are still open questions concerning 
the basic aspects of the molecular biology and pathogenicity of Cj, including roles of 
its HtrA [197]. 
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2.2 MATERIALS & METHODS 
 
This section describes the HtrA heterologous over-expression and the purification 
procedure of the recombinant protein. 
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2.2.1 Cj-HtrA Plasmid Expression Vector Construction 
The Cj-HtrA plasmid expression vector was prepared in the Laboratory of 
Microbiology, Department of Biology, directed by Prof. Dr. Steffen Backert at the 
Friedrich-Alexander Universität Erlangen-Nürnberg, Germany, according to the 
procedure described by Boehm et al. [196]. After amplification of the gene from 
genomic DNA excluding predicted signal peptides, the Cj-HtrA aa 17-472 
(GenBank: EAQ72866.1) sequence was cloned: PCR fragments flanked by 
restriction sites for BamHI/XmaI were cloned into the pGEX-6P-1 (GE Healthcare) 
vector multi-cloning area to generate the GST (Glutathione-S-Transferase)-fusion 
protein. The signal peptide from aa 1-16 was cut-off to avoid problems. The vector 
also carries a recognition sequence located immediately upstream from the multi-
cloning site that represents the PreScission Protease site for the removal, if desired, 
of the GST-tag. 
 
 
 
Figure 2.4: Amino acid sequence of the HtrA from Cj 81-176 (GenBank: EAQ72866.1), composed of 
472aa (51kDa); signal peptide sequence is highlighted in grey. 
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Figure 2.5: At the top of the figure, schematic representation of the cloning of the gene of interest 
(htra gene) into the MCS of the pGEX-6P-1 plasmid vector, between restriction sites BamHI and 
XmaI. At the bottom, representation of the final gene construct (6347bp) with the htra gene and other 
main components (GST gene, tac promoter, the lac operon system and the restriction sites). 
 
 
 68 
 
2.2.2 HtrA Over-expression and Standard Purification 
  
2.2.2.1 Purification Principles 
The standard purification protocol adopted provides the use of a Glutathione 
Sepharose medium: indeed, GST-tagged proteins are easily purified from bacterial 
lysates by affinity chromatography using glutathione immobilized to a matrix such as 
Sepharose (see Fig. 2.6). When applied to the affinity medium at low flow rate, the 
tagged proteins bind to the ligand, and impurities are removed by washing with 
binding buffer. Tagged proteins are then eluted from the Glutathione Sepharose 
under mild, non-denaturing conditions using reduced glutathione, to preserve both 
protein structure and function. Eventually, if separation of the cloned protein from 
the GST-tag is desired, the tagged protein can be treated with an appropriate site-
specific protease (Paragraphs 2.2.2.3 and 2.2.2.4). 
 
 
Figure 2.6: Terminal structure of Glutathion Sepharose. Glutathione is specifically and stably coupled 
to Sepharose by reaction of the SH-group with oxirane groups obtained by epoxy-activation of the 
Sepharose matrix. The structure of Glutathione is complementary to the binding site of Glutathione-S-
transferase. 
 
 
2.2.2.2 HtrA over-expression and purification 
E.coli cells transformation protocol used provides the addition of 1µL of the plasmid 
vector into 20-50μL of competent cells in a microcentrifuge tube, gently mixing by 
flicking the bottom of the tube. Competent cells were thaw on ice and, after the 
addition of the plasmid, were still maintained at 4°C for 30 min. Subsequently, the 
cells were placed in a water bath at 42°C for 45s allowing the heat shock happening. 
At the end, 800µL of LB or TB were added and the mixture was incubated for 1h at 
37°C, under mild shaking. Cells were plated onto LB agar containing the appropriate 
antibiotic and incubated at 37°C overnight to allow the growth.  
A small quantities of that cells harbouring pGEX-6P-1·HtrA were dispersed (pre-
inoculated) in 50mL of LB or TB supplemented with the appropriate antibiotic 
(Ampicillin to a final concentration of 50µg/mL; Chloramphenicol to a final 
concentration of 34µg/mL) and allowed to grow overnight at 37°C under mild 
shaking.  
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Subsequently, this aliquot was added to 1L of LB or TB  (1:20 ratio), with the proper 
antibiotic and place, under agitation, in the appropriate conditions of temperature and 
time (depending on the specific trial) until 0.6 OD600. A small volume (1mL) has 
been kept aside, treated with SB
1
 1X at 100°C for 10 min (hereinafter referred to as 
“uninduced” sample). Protein expression was induced by adding isopropyl-β-D-1-
thiogalactopyranoside (IPTG) 1M, to a final concentration of 0.5mM, and incubating 
the bacterial cells at the appropriate conditions of temperature and time. At the end, 
OD600 was measured and, as before, 1mL of the culture was treated with SB 1X 
(hererinafter referred to as the “induced” sample) and the remaining cells were 
harvested by centrifugation at 6000rpm for 15 min at 4°C and suspended in 10mL of 
PBS 1X with PMSF 100mM at a final concentration of 1mM and in the presence of 
the 3 protease inhibitors E64, Aprotinin and Leupeptin 1000X, to 1X as final 
concentration. Resuspended cells were lysate with the Constant Cell Disruption 
System (Constant Systems Ltd; pressure set to 1.35kbar): after centrifugation at 
15000rpm for 30 min at 4°C, 20µL of the supernatant were treated with SB 2X and a 
small quantity of the pellet was treated with SB 5X. Then, the set up for the affinity 
column, necessary to subsequent purification of the protein, was prepared 
equilibrating 500µL of Glutathione Sepharose 4B with PBS 1X. The soluble fraction 
was loaded onto the resin and incubated by rotation at 4°C overnight. Then, for the 
second time, the suspension was loaded onto the affinity column, the Flow-Through 
(FT) was collected and the subsequent solutions were added, in order: PBS 1X and 
Tris 50mM/Tween 0.1% pH 7.5. A Tris 50mM/GSH 10mM pH 8.0 freshly prepared 
solution was added at the end, in order to recover the protein from the resin: to do 
this, three aliquot of 1mL were added (the first two aliquot were eluted after a 30 min 
incubation at ambient temperature, whereas the third aliquot was immediately eluted 
from the column). All the fractions eluted from the column were treated with SB 2X 
and all the samples were submitted to SDS-PAGE (Gradient PreCast Gel 4-12%, 
Mes 1X, ΔV = 200V, current intensity: variable, P = 50W), after which the 
polyacrylamide gel was washed with water, stained with Coomassie Blue and 
destained using acetic acid 10%. The fractions containing the protein were combined 
and concentrated through centrifugation over a nitrocellulose membrane (Millipore 
Amicon Ultra; cut-off: 10kDa). The concentrated fraction was then analysed by 
Analytical Gel Filtration, FPLC, with a column for Size-Exclusion Chromatography 
(SuperdexTM 200 Increase 10/300GL, GE Healthcare) equilibrated with Tris 50mM 
pH 7.5 as elution buffer. Molecular weights of the proteins or fragments associated 
with the different peaks were determined with the use of a calibration curve obtained 
from commercial protein standards. 
During the purification steps, all the aliquots (protein, FT, washes with buffer) were 
constantly maintained at 4°C because of the suspected low stability of the HtrA 
protease (as common for most protein belonging to this class). 
                                                          
1
 A mixture of bromophenol blue, glycerol, 2-mercaptoethanol and SDS: together with the heat 
treatment, it favours the complete denaturation of all proteins in the sample necessary for the 
subsequent SDS-PAGE analysis. 
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2.2.2.3 HtrA Purification removing GST-tag with PreScission Protease: 
Principles of GST-tag removal 
Principles underlying the method, as its practical aspects, can be found in the useful 
GE Healthcare Handbook “Recombinant Protein Purification” and the experimental 
work done is based on this exhaustive reference. In addition to the purification of the 
HtrA protease with the GST-tag, purification of the protein without the fusion tag 
was also performed, using the PreScission Protease whose recognition sequence has 
been inserted in the pGEX vector for this purpose. For the removal of the GST 
moiety (a naturally occurring protein with MW of 26kDa), the tagged protein can be 
digested with PreScission Protease (or another appropriate site specific protease) 
while bound to Glutathione Sepharose or, alternatively, after elution. Cleavage of 
GST-tagged protein bound to the column/bulk medium eliminates the extra steps of 
separating the released protein from GST, since the GST-tag remains bound. The 
cleaved target is then eluted using binding buffer. Another important feature is that 
PreScission Protease itself has a GST-tag and therefore will bind to Glutathione 
Sepharose: it will thus not co-elute and contaminate the cleaved target protein. As a 
practical recommendation, cleavage with PreScission Protease is very specific, but 
the maximum cleavage is obtained in the cold (the protein is most active at 4°C), 
thus improving the stability of the target protein. 
 
 
2.2.2.4 HtrA Purification removing GST-tag with PreScission Protease: 
Purification and Cleavage  
Cleavage of GST-tag using PreScission protease can be done in two different ways, 
named on-column and off-column cleavage. In both cases, the cell lysate is added to 
Glutathione Sepharose but, in the off-column method, this step is followed by elution 
with reduced glutathione and, after, by the cleavage of the eluted tagged protein with 
PreScission Protease. Finally, by passing the solution through the column, only the 
cleaved protein is allowed to be collected. By contrast, in the on-column method the 
tagged protein is cleaved with PreScission Protease directly in the column and the 
Flow Through with the cloned protein without the GST-tag is collected. At the end of 
these methods, the protein is usually analyzed by means of SDS-PAGE or mass 
spectrometry. Following the protocols described in the GE Healthcare Handbook, 
either off-column and on-column method were performed: in both cases, 500µL of 
Glutathione Sepharose were used and the protease inhibitors PMSF, E64, Leupeptin 
and Aprotinin (to the same final concentration reported above) were added to the cell 
lysate.  
Great care was used to keep all the samples, during all the steps, at 0°C or at 4°C 
during the incubation time. In addition, 50µL of PreScission Protease were added in 
both methods and the following composition characterized the Elution and Cleavage 
Buffer used: 
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Elution Buffer: 50mM Tris-HCl, 10mM reduced glutathione, pH 8.0 
Cleavage Buffer: 50mM Tris-HCl, 150mM NaCl, 1mM EDTA, 1mM DTT, pH 7.0 
 
After purification and cleavage, the samples were submitted to SDS-PAGE and the 
fractions with a detectable quantity of protein were combined, concentrated and 
analysed through Analytical Gel Filtration, FPLC, with column for Size-Exclusion 
Chromatography (SuperdexTM 200 Increase 10/300GL, GE Healthcare) equilibrated 
with Tris 50mM pH 7.5 as elution buffer. 
 
 
2.2.3 Western Blot Analysis  
In order to investigate the possible HtrA degradation pathway, part of the samples 
obtained from the previous expression and purification steps were used to carry out a 
Western Blot Analysis. To do this, proteins of the samples were separated using gel 
electrophoresis: in order to make the proteins accessible to antibody detection, they 
were moved from within the gel onto a nitrocellulose membrane made through 
electroblotting (30V, 1h) using the Transfer Buffer. Since the membrane has been 
chosen for its ability to bind protein and as both antibodies and the target are 
proteins, steps must be taken to prevent the interactions between the membrane and 
the antibody used for detection of the target protein. Blocking of non-specific 
binding were achieved by placing the membrane in BSA 3% in TBS 1X for one hour 
under gentle agitation. After blocking, three washes with TTBS for 15 min were 
done and 10mL of the primary monoclonal mouse antibody IgG1 anti-GST (1:100 in 
TTBS; stock solution at 200µg/ml purchased from Santa Cruiz Biotechnology) were 
added to the membrane, maintaining it under gentle agitation for 2 hours. Then, three 
washes with TTBS for 15 min were done and 10mL of the anti-mouse IgG secondary 
antibody-peroxidase (1:10000 in TTBS; stock solution purchased from Sigma) were 
incubated with the membrane under gentle agitation. Finally, three washes with 
TTBS for 15 min were done and the membrane was submitted for chemiluminescent 
detection adding to it a freshly prepared luminol/hydrogen peroxide solution and 
using as Chemiluminescent Imaging System the instrument Kodak Image Station 
4000MM Pro with the Carestream Molecular Imaging Software. 
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2.3 RESULTS & DISCUSSION   
 
In this section, results obtained after several attempts of expression and purification 
of the HtrA protease will be illustrated and critically analyzed. Some Bioinformatics 
tools were also exploited to understand how to solve its structure and that of the same 
protein in Helicobacter pylori. 
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2.3.1 HtrA Bioinformatic analysis  
 
2.3.1.1 Bioinformatic analysis 
Crystal structure of HtrA from Cj could be solved either using SeMet isomorphous 
derivatives with the SAD/MAD techniques or, more likely, through Molecular 
Replacement (MR), owing to the high sequence and structural homology with other 
known proteins. Indeed, a similarity analysis using BLASTp software 
(www.blast.ncbi.nlm.nih.gov/Blast.cgi) with amino acid sequence of HtrA of Cj 
(GenBank: EAQ72966.1) as input sequence, identified high homology (41%) with 
Chain A in DegP24 of E. coli (PDB ID: 3CS0 A). The two sequences have been 
compared using ClustalW software (www.ebi.ac.uk/Tools/msa/clustalw2/). The 
homology is higher in the central portion and lower at the N- and C-terminus. The 
program also identified some putative conserved domains, in particular the Trypsin 
like domain and the PDZ domain of trypsin-like serine proteases, as expected.  
 
 
Figure 2.7: Comparison of amino acids sequence of HtrA from Cj and DegP24 from E. coli (* for 
identical residues, : for conserved residues and . for semiconserved residues) 
 
Structural homology was confirmed using two different protein structure homology-
modelling server, SWISS-MODEL (swissmodel.expasy.org/) and Phyre2 
(www.sbg.bio.ic.ac.uk/phyre2/html/page.cgi?id=index): homology modelling is 
currently the most accurate method to generate reliable three-dimensional protein 
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structure models. The methods predict the three-dimensional structure of a protein 
sequence using the principles and technique of homology modelling. Since the 3D 
structure of a protein is more conserved in evolution than its amino acid sequence, a 
protein sequence of interest (the target) can be modelled with reasonable accuracy on 
a very distantly related sequence of known structure (the template), provided that the 
relationship between target and template can be discerned through sequence 
alignment. The results obtained from these two independent modelling, based on the 
same principles, converge toward the same structure of the E. coli DegP (PDB ID: 
2ZLE). The degree of structural homology (template identity) was 41.6% and 44% 
from SWISS-MODEL and Phyre2, respectively, confirming not only a sequence 
homology but, also, a good similarity in the three-dimensional folding. In addition, 
Phyre2 report a secondary structure and disorder prediction, in which it appears that 
the percentages of disordered regions, α-helix and β-strand are, respectively, 28%, 
19% and 35%. Through bioinformatics tools it is possible to say that there is a good 
chance to solve the structure of HtrA from Cj using MR, thanks to some hopeful 
templates. 
            
Figure 2.8: On the left, cartoon representation of the three-dimensional model generated by Phyre2 
and, on the right, the structure obtained from SWISS-MODEL. 
 
However, it is more interesting to see if there is sequence homology with some HtrA 
from Helicobacter pylori: if so, the structure of the HtrA from Hp could be solved 
using ab initio or Molecular Dynamics methods. Once obtained the structure of HtrA 
from Cj, it cannot be used as a reference structure for the determination, via MR, of 
the three-dimensional model of Hp-HtrA because MR requires the knowledge of 
diffracted intensities, structure factors for each reflections etc. However, this is not 
the case because obtaining the crystal of the HtrA from Hp is hard, owing to its 
instability (without the crystal, it is impossible to obtain the experimental data 
required for resolution via MR). Effectively, by aligning the amino acid sequence of 
HtrA in Cj against the sequence of the HtrA from a common strain of Hp (GenBank: 
EJC53984.1) proves that there is a high degree of homology (46%). 
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Figure 2.9: Comparison of amino acids sequence of HtrA from Cj and HtrA from Hp P-41 (* for 
identical residues, : for conserved residues and . for semiconserved residues) 
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2.3.2 Over-expression and purification 
Several attempts have been made in order to obtain a sufficient amount of Cj HtrA 
pure protein: the main variables include the type of E. coli strain, culture medium, 
temperature and time. The HtrA expression was evaluated in the course of several 
tests in which these conditions were varied but, in all cases, only a small quantity of 
the protein was obtained, preventing the possibility of crystallizing it. Moreover, the 
purification protocols failed to provide the protein in a very pure form, required for 
any crystallization trials. Results are summarized and, together with them, also 
possible explanations are given. 
 
First Attempt 
In the first attempt, E. coli BL21(DE3) competent cells were transformed with the 
plasmid vector and used for pre-inoculation and inoculation at 30°C for 3h, with LB 
as growth medium. The protocol reported in the experimental section was followed 
and the result of HtrA expression was evaluated from SDS-PAGE and from the size-
exclusion chromatography-FPLC analysis. No purification with PreScission Protease 
was done.  
 
Figure 2.10: SDS-PAGE gel corresponding to the uninduced sample (ni), induced sample (i), the 
supernatant (s), the Flow Through (FT), the washes with Buffer (wash and wash’) and the three 
eluted fractions with Glutathione Buffer, in order (1, 2, 3). On the left, molecular weights of the 
protein markers. 
 
Owing to its cytoplasmic localization, HtrA is a soluble protein and, as a 
consequence, it is expected in the supernatant. As the gel shows, only a weak 
expression of the tagged protein was obtained: slightly above the signal of the protein 
marker at 66kDa, near the molecular weight of HtrA with the GST-tag (79kDa), 
three bands with decreasing intensity could be identified in the eluted fractions. 
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However, other bands at lower molecular weights appear in the gel, particularly near 
the signal of the protein marker at 45kDa, and compatible with HtrA without GST-
tag (53kDa) and, although less easily visible, near 25kDa and relative to the free 
GST moiety (26kDa). Unfortunately, other bands appear in the gel and this poses 
into question the efficacy of the purification protocol and/or suggests susceptibility to 
degradation of the HtrA protease. These suspects are confirmed also after gel 
filtration experiment: as can be seen in Fig. 2.11, at least six different peaks are 
visible. Given the known molecular weight of HtrA·GST, one would expect a peak 
around 13.5ml: at this elution volume there is a relative intense peak that can be 
attributed to the HtrA·GST complex. The same can be said for the peak relative to 
HtrA, which should elute roughly at 14.3ml. However, HtrA is not a monomer in its 
native/inactive form but, as demonstrated, a homotrimer
2
; furthermore it could result 
in the formation of oligomers with higher molecular weights and this is more likely 
when the protein solution is concentrated. Assuming that HtrA and HtrA·GST are 
present as homotrimers, they should elute with two peaks at 12.2ml and 11.4ml, but 
none is visible in this region of the gel filtration curve. In any case, due to the low 
absorbance of the putative peak, only a low amount of protein (free or in complex 
with GST) was probably obtained. Finally, free GST should elute at about 15.7ml: 
however, no peak is observed. This could be due to aggregation of free GST to give 
oligomers with greater molecular weights. Another possible explanation for the 
unsatisfactory protein yield concerns the formation of the so-called inclusion bodies: 
recombinant protein over-expression in bacterial hosts often results in insoluble and 
misfolded proteins directed to inclusion bodies. These aggregates are deleterious, 
because they sequester the protein reducing the yield of the process; furthermore, 
attempts to prevent protein aggregation are in general unsuccessful and when 
inclusion bodies are formed, (partial) recovery of the native and correctly folded 
protein are difficult and time-consuming.  
 
                                                          
2
 Protein expression in an heterologous system can result in a monomeric form as well as in one or 
more different oligomeric forms. The oligomeric form with which the protein is expressed does not 
necessarily coincide with that present in physiological conditions within the organism. Not necessarily 
HtrA is expressed in its native/inactive form as homotrimer but may be secreted in the form of higher 
oligomeric species or as a monomer. The aggregation state that can be deduced from gel filtration 
experiments depends on the pH and chemical composition of the buffer in which the protein is eluted, 
the protein concentration in solution and not only. 
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Figure 2.11: Analytical gel filtration after purification and concentration (absorbance measured at 
λ=280nm). The upper-right panel shows the calibration curve obtained with five protein standards of 
known MW (note that the graph was created having a logarithmic scale for the y-axis). 
 
Looking better to the SDS-PAGE gel, it is possible to see a band compatible with the 
presence of tagged HtrA also in the non induced sample: this may seem strange but, 
in some expression systems, this is quite common. Indeed, a basal level of expression 
is possible, especially for some kind of bacterial strains, as is the case of E. coli 
BL21(DE3) cells. In addition, if the protein being expressed is toxic for cells, this 
can explain the low amount of protein detected both in SDS-PAGE and in the 
chromatogram. A basal level of expression before the addition of IPTG is expected, 
but after the induction the cells started to produce the protein and its toxic effects are 
manifested from the beginning: this causes cell death and prevents protein 
expression.  
Other growth conditions have been tested but, even in these cases, expression was 
not as satisfactory as expected. Also using a more nutrient culture medium as the 
Terrific Broth (TB), instead of the Luria-Bertani (LB), provides the same results.  
 
Second Attempt 
To overcome a possible toxic effect of the protein already prior to induction, a 
different commercial available E. coli strain has been used: BL21(DE3)pLysS cells 
carry both the DE3 lysogen and the plasmid pLysS. pLysS constitutively expresses 
low levels of T7 lysozyme, which reduces basal expression of recombinant genes by 
inhibiting basal levels of T7 RNA polymerase (T7 lysozyme is a natural inhibitor of 
T7 RNA polymerase). This strain was tested in different conditions of expression, 
i.e. by varying temperature and time during the inoculation step. However, as seen 
from Fig. 2.12, a basal level of expression is still present and, due to the minimum 
difference between band intensity, it is difficult to judge if there was or not 
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expression after induction. As in the first attempt, other bands are present, not only 
associated with HtrA and free GST but relative to other proteins or fragments, part of 
which probably derived from HtrA degradation. 
 
 
Figure 2.12: SDS-PAGE gel corresponding to expression trials at various conditions of time and 
temperature (in this case, p represents the pellet sample). 
 
 
Third Attempt 
In the third attempt a different E. coli strain was used, in particular E. coli BL21 
cells. In addition, purification protocol based on the removal of the GST-tag with 
PreScission Protease was implemented, either with the off-column and on-column 
cleavage. Remove the GST-tag has the advantage of allowing the crystallization and 
structure determination of the protein itself: without the tag, the protein more likely 
adopts the native conformation, and the structure so obtained reflects the real three-
dimensional conformation of the protein. This is particularly true in the case in which 
the tag have a considerable molecular weight, as it is for GST: the main drawback is 
probably this, meaning that the protein of interest is attached to GST, altering its 
native state. However, GST-tag at the N-terminus of recombinant proteins have 
different advantages: because GST rapidly folds into a stable and highly soluble 
protein upon translation, inclusion of the GST-tag often promotes greater expression 
and solubility of recombinant proteins than expression without the tag. In addition, as 
discussed in precedence, GST-tagged fusion proteins can be purified or detected 
based on the ability of GST to bind its substrate, glutathione. Unfortunately, the use 
of E. coli BL21 cells and the cleavage of the tagged HtrA with PreScission Protease 
does not produce enhancements because numerous bands and peaks are still visible 
either in SDS-PAGE and in the chromatogram relative to the size-exclusion 
chromatography-FPLC.  
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Among the various difficulties inherent with the cleavage method, it is possible to 
identify some of it that have a prominent role and are, probably, largely responsible 
for the failure of the cleavage. When GST-tagged proteins are not cleaved 
completely, there are different possible critical points in the procedure: first, it is 
possible that the ratio of PreScission Protease to GST-tagged protein is not optimal. 
This requires a preliminary quantification of the protein before the cleavage, but the 
estimate of the amount of protein from a gel is not an easy task; in any case, the 
optimal amount must be determined empirically. Second, there is the possibility that 
the incubation time and/or enzyme concentration is not sufficient for complete 
cleavage of the protein from the GST-tag: in this case, the advice is to increase the 
incubation time for the cleavage reaction. Increasing the reaction time to 20 hours or 
more should improve cleavage as long as the tagged protein is not degraded by the 
extended incubation period. Alternatively, increasing the amount of the enzyme used 
for cleavage can represents a valid solution. Third, it is also possible that the specific 
cleavage site for the protease has been altered during cloning of the tagged protein 
or, fourth, the presence of cleavage enzyme inhibitors is interfering with the cleavage 
reaction. When multiple bands are observed after electrophoresis/Western Blotting 
analysis (see Fourth Attempt) of the cleaved target protein, possible causes are the 
occurrence of proteolysis in the host bacteria prior to the cleavage reaction or the 
presence, in the target protein itself, of recognition sequences for PreScission 
Protease or other cleavage proteases. With respect to the former cause, the 
determination when the extra bands appear is needed, as it is also necessary to verify 
that additional bands are not present prior to PreScission cleavage. In regard to the 
latter cause, it is necessary to check the sequence of the tagged protein to determine 
if it contains recognition sequences for the cleavage enzymes. Last but not least, it is 
of great importance to find the correct amount of resin (Glutathione Sepharose), 
because an excess of beads results in unspecific protein binding and too few beads 
result in a low protein yield: owing to these considerations, it is necessary to check 
that the amount of tagged protein does not exceed the capacity of the Glutathione 
Sepharose media (in most purification, however, the medium is not saturated with 
tagged protein). Despite all these suggestions have been taken into account during 
the experimental optimization of the cleavage protocol, no improvements were 
observed. 
 
Fourth Attempt 
To investigate further the presence of several bands observed after electrophoresis, a 
Western-Blot Analysis has been made using anti-GST primary antibody and a 
secondary antibody carrying the horseradish peroxidase enzyme that, upon addition 
of its substrate (luminol in the presence of hydrogen peroxide) cleaved it, generating 
a chemiluminescent reaction product which luminescence is proportional to the 
amount of protein. The result is shown in Fig. 2.13, in which the dark signals are due 
to the presence of GST free or bound to HtrA (or to possible fragments).  
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Among the different samples analysed, it is of relevance the discussion of some of it, 
particularly samples 5, 7, 8, 9, 10 and 11. Sample 5 represents the first eluted fraction 
with the Glutathione Buffer during the purification procedure without the use of 
PreScission Protease and the bands clearly visible represent different intermediate 
products derived from the degradation of the tagged HtrA. The number, intensity and 
heights of these bands confirm the existence of a degradation pathway of the tagged 
protein, probably due to its autoproteolytic activity. Samples from 7 to 11 are relative 
to fractions 2, 5, 6, 7 and 8 in the chromatogram of Fig. 2.14. Also in this case it was 
obtained a not clean chromatogram with several peaks. HtrA·GST should elute 
roughly at 14.2ml, but at this elution volume there is a shoulder in the curve. The 
shoulder in the curve probably cover the HtrA·GST peak: however, it is also possible 
that HtrA elute not as a monomer but in an higher oligomeric form, visible at a lower 
volume. Differently, HtrA should elute near 15.2ml but, also in this case, at this point 
is present a shoulder in the curve, even if with a very low absorbance. Assuming that 
HtrA and HtrA·GST are present as homotrimers, they should elute with two peaks at 
12.4ml and 11.4ml: these elution volumes matches with the fractions 6 and 5.  
Lastly, free GST should elute at about 16.9ml but no peaks are visible.  
It is clear that HtrA undergo rapid degradation, probably due to its autoproteolytic 
activity, in which a series of different intermediate products, with also attached GST, 
are generated. This happens despite the continuous control of the temperature, 
constantly maintained at 0°C, and despite the presence of different serine protease 
inhibitors. These protease inhibitors are essential because when cells are lysed some 
proteases, many of which are contained within lysosomes, are released. These 
proteases, if freely present in the lysate, would destroy any protein or any other 
component of interest. However, in the present case they do not appear sufficient to 
prevent HtrA degradation. This is the reason why it was decided to continue the 
study on a HtrA mutant characterized from the substitution, in the active site, of one 
amino acid: in particular, the critical serine in the catalytic triad was mutated to 
alanine in order to prevent autoproteolysis. It is expected that this substitution makes 
the protein more stable, facilitating in this way its purification and crystallization. 
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Figure 2.13: Western-Blot Analysis of Prestained Protein Molecular Weight Markers (1), ni (2), i (3), 
s (4), first eluted fraction (5), FT (6), Fraction 2 (7), Fraction 5 (8), Fraction 6 (9), Fraction 7 (10), 
Fraction 8 (11), Fraction after incubation with PreScission Protease (12). Fractions 2, 5, 6, 7 and 8 are 
relative to purification without PreScission Protease (see chromatogram in Fig. A.14). 
 
 
 
Figure 2.14: Analytical gel filtration after purification, cleavage with PreScission Protease and 
concentration; fractions of major interest are indicated in bold blue. The upper-right panel shows the 
calibration curve obtained with five protein standards of known MW (note that the graph was created 
having a logarithmic scale for the y-axis). 
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Fifth Attempt 
Competent E. coli BL21 cells were transformed in the presence of the pGEX-6P-1  
vector plasmid carrying the mutated htra gene; after inoculation and induction with 
IPTG, pellet were harvested and resuspended in PBS 1X in the presence of PMSF 
1mM. After lysis the supernatant was incubated over night at 4°C with Glutathione 
Sepharose 4B. FT was collected and the resin washed with 10mL of Cleavage 
Buffer; 70µL of PreScission Protease were added directly on-column and the mixture 
was placed under agitation over night at 4°C. The next day, FT was collected and the 
resin was washed with the Cleavage Buffer; at the end, a single wash with the 
Elution Buffer was done. All the fractions were submitted to SDS-PAGE and, after 
analyzing the gel obtained, fractions containing the cleaved protein (1, wash and 
wash’ in Fig. 2.15) were combined and concentrated. The concentrated protein was 
analyzed in a gel filtration experiment (Fig. 2.16), after which some fractions were 
run in a SDS-PAGE. 
 
 
 
Figure 2.15: SDS-PAGE gel after expression and purification with PreScission protease; 1 and 2 
represent the FT after incubation over night of Glutathione Sepharose 4B with the site-specific 
protease, wash and wash’ were obtained after washing of the column with Cleavage Buffer and 
wash’’ after the same procedure but using Elution Buffer. 
 
SDS-PAGE of fractions indicated in Fig. 2.16 reveals the presence of the cleaved 
protein only in fraction 4, which appears as a principal band in the gel; however, bare 
visible bands at different molecular weights were detected. Although fraction 4 is 
more clean than those obtained in precedent attempts, it is not yet enough to proceed 
with crystallization trials. 
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Figure 2.16: Analytical gel filtration after purification, cleavage with PreScission Protease and 
concentration. Fractions of major interest are indicated in bold blue. 
 
After gel filtration experiment, it was decided to investigate the stability of the HtrA 
mutant with the aim to understand its stability relative to that of Cj-HtrA. Fig. 2.17 
reported the result after Western-Blot analysis of significant fractions collected in the 
previous expression and purification steps: 
 
 
Figure 2.17: Western-Blot Analysis of Prestained Protein Molecular Weight Markers (leftmost) and 
various samples which significance is discussed above in the text. 
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The presence of the bands relative to HtrA·GST in supernatant and FT is expected 
because these samples were obtained before the PreScission cleavage. Conversely, 
the presence of the bands relative to HtrA·GST in samples 1, 2, wash and wash’ 
looks suspicious as they were collected after incubation overnight with the site-
specific protease. However, is to be considered that the same bands are quite weak in 
SDS-PAGE gel and that the Western-Blot analysis is extremely sensitive. The band 
at 25kDa in wash’’ is expected because it derives from the washing with GSH 
(competitive ligand) which determines the release of GST moiety bound to the resin. 
It is also expected the absence of any bands in fractions derived from gel filtration 
(only a merely detectable band is present in fraction 8, more likely due to eluted 
GST). This also confirm that the band in fraction 4 (seen from SDS-PAGE) is 
relative to cleaved HtrA. In light of this, the cleaved protein in fraction 4 was 
concentrated (Millipore Amicon Ultra cellulose membrane; cut-off: 10kDa) to 7 
mg/ml for crystallization purposes: the effective protein concentration was 
determined by UV/Vis Spectroscopy (280nm, Thermo Scientific NanoDrop 
2000/2000c UV-Vis spectrophotometer). Crystallization conditions were identified 
using vapour diffusion technique performed in sitting drop variant and Oryx8 
crystallization robot (Douglas Instruments). General conditions trials were performed 
mixing 0.30 μl of protein solution with 0.30 μl of precipitant on 96-well plates 
(Douglas Instruments), containing 75 μl of precipitant in every well, allowing the 
crystallization at the constant temperature of 20°C. For the first crystallization trial 
the Structure Screen 1+2 HT-96 kit (Molecular Dimensions) was used. 
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2.3.3 Conclusions 
 
Attempts to obtain Cj-HtrA protease in a pure form making use of heterologous over-
expression in a bacterial host and successive purification was difficult to reach. 
Further investigations are required in order to understand more in depth the protein 
instability and to perform a better protocol. Although preliminary, the results 
obtained for mutant HtrA are not satisfactory: despite the HtrA mutant seems to be 
less prone to autodegradation, as seen from Western-Blot analysis, the protein yield 
is low as in the case of wt-HtrA and even after purification steps the fractions are not 
sufficiently pure for crystallization purposes.  
About the instability of HtrA from Cj, there are at least two possible explanations: 
first, instability can be dictated merely by the primary amino acid sequence of the 
protein, without particular biological reasons. Second, and more interestingly, behind 
the instability of the HtrA protease there may be physiological and biological 
implications. In 2008, Sacchettini et al. [150] have determined the structure of HtrA 
from Mycobacterium tubercolosis (Mtb): the crystal structure revealed tetrapeptides 
bound to the protease active site and to PDZ domains. These peptides most likely 
derived from autoproteolytic processing of HtrA. Based on this and other 
observations, they speculated that the protease might regulate itself by its 
autoproteolytic products; furthermore, the binding of tetrapeptides should have an 
effect on the substrate specificity, might regulate the activity of the protease domain 
and might have significant importance in HtrA-associated virulence of Mtb. In 
addition, other studies reported on the instability of HtrA: in 2011 it was observed 
autodegradation both in vivo and in vitro (with purified wt-HtrA) for HtrA from Cj 
[193]. However, it was noted that HtrA from E. coli was less prone to 
autodegradation and this was explained on the basis of disulfide bridges, absent in 
Cj-HtrA but present in HtrA from E. coli. Other authors have focused on a possible 
biological role of different HtrA [172] [198] but, nowadays, the physiological 
consequences of the observed autocleavage remain unclear. 
The presence of multiple bands in SDS-PAGE gels even after purification with or 
without PreScission Protease suggests a residual autoproteolytic activity and possible 
aspecific binding to the resin (this can be inferred from bands at higher molecular 
weights with respect to that of HtrA bound to GST) from proteins derived from lysis 
of E. coli cells. These proteins were co-eluted with the cleaved HtrA and hinder 
crystallization trials, together with the fragments generated by autocatalytic cleavage. 
In addition, it seems strange the presence, evidenced from Western-Blot analysis, of 
the band relative to HtrA·GST in the fractions after site-specific cleavage: this shows 
that not all the HtrA bound to GST was cleaved during the 24h incubation. It can be 
speculated a possible alteration of the overall structure of the protease caused by the 
GST moiety: GST is a non-small protein that can alter the protein conformation in a 
manner such that it is incorporated in a non exposed region. This, in turn, can be 
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responsible for the incapacity of PreScission Protease to cleave correctly the 
recombinant protein.  
To further increase the stability of HtrA a double or triple mutant may be necessary. 
With a more stable protein, both expression and purification procedures should 
benefit from this; reducing the induction/expression time can also counteract certain 
propensity of the protein to degrade itself. In addition to the problem of instability, 
there are other weakness in the procedure such as the protein tag: the GST-tag are 
useful because it often promotes greater expression and solubility of recombinant 
proteins. However, HtrA is a cytoplasmic protein: owing to this, it is likely that it is a 
soluble protein and the GST-tag appears probably not necessary. An His6-tag is 
smaller and, thanks to this, it can be maintained attached to the protein even during 
the crystallization step. Another possible improvements could include growth in a 
more acidic pH medium, in order to resemble the environment in which Cj-HtrA is 
secreted. 
However, the crystal structure, combined with other experimental evidences, can 
provide clues about the physiological and pathological role of HtrA protease in Cj 
and, by inference, even in Hp: this underlines the importance of proceeding in 
attempts to express and purify HtrA protein or its mutants. 
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Appendix A3 
 
In this Appendix, the space group of crystals analyzed in the thesis are reported, in 
order to highlight the geometrical features. 
 
 
 
 
 
 
 
 
 
 
 
                                                          
3 This Appendix is taken referring to International Tables for Crystallography (2006) Vol. A, Ch. 7.1, 
pp.112-717. 
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Appendix B 
 
Amino acids 
Alanine Ala A 
Arginine Arg R 
Aspartic acid Asp D 
Asparagine Asn N 
Cysteine Cys C 
Glycine Gly G 
Glutamine Gln Q 
Glutamic acid Glu E 
Histidine His H 
Isoleucine Ile I 
Leucine Leu L 
Lysine Lys K 
Methionine Met M 
Phenylalanine Phe F 
Proline Pro P 
Serine Ser S 
Threonine Thr T 
Tyrosine Tyr Y 
Tryptophan Trp W 
Valine Val V 
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